References

cardio

Кардиология

Kardiologiia

0022-90402412-5660

Kardiomag

10.18087/cardio.2025.6.n2921

cardio-2921

Research Article

МНЕНИЕ ЭКСПЕРТОВ

OPINION OF EXPERTS

Психические расстройства у пациентов с сердечно-сосудистыми заболеваниями. Консенсус рабочих групп Российского кардиологического общества и Российского общества психиатров

Mental Disorders in Patients with Cardiovascular Diseases. Consensus Statement by the Task Force of the Russian Society of Cardiology and the Russian Society of Psychiatrists

https://orcid.org/0000-0003-2206-8922

Белялов

Ф. И.

Belialov

F. I.

д.м.н., профессор кафедры геронтологии, гериатрии и клинической фармакологии Иркутской государственной медицинской академии последипломного образования

Москва, Россия

MD, Professor, Department of Gerontology, Geriatrics and Clinical Pharmacology

Moscow, Russia

fbelyalov@mail.ru

Вельтищев

Д. Ю.

Veltishchev

D. Yu.

д.м.н., профессор кафедры психиатрии, Российского национального исследовательского медицинского университета имени Н.И. Пирогова

Москва, Россия

MD, Professor, Department of Psychiatry

Moscow, Russia

Волель

Б. А.

Volel

B. A.

д.м.н., профессор, заведующий кафедрой психиатрии и психосоматики Первого Московского государственного медицинского университета имени И.М. Сеченова

Москва, Россия

MD, Professor, Head of the Department of Psychiatry and Psychosomatics

Moscow, Russia

Гарганеева

Н. П.

Garganeeva

N. P.

д.м.н., профессор кафедры общей врачебной практики и поликлинической терапии Сибирского государственного медицинского университета

Томск, Россия

MD, Professor, Department of General Medical Practice and Polyclinic Therapy

Tomsk, Russia

Копылов

Ф. Ю.

Kopylov

F. Yu.

д.м.н., профессор кафедры кардиологии, функциональной и ультразвуковой диагностики Первого Московского государственного медицинского университета имени И.М. Сеченова

Москва, Россия

MD, Professor, Departments of Cardiology, Functional and Ultrasound Diagnostics

Moscow, Russia

Ларева

Н. В.

Lareva

N. V.

д.м.н., профессор, заведующий кафедрой терапии Читинской государственной медицинской академии

Чита, Россия

MD, Professor, Head of the Therapy Department

Chita, Russia

Медведев

В. Э.

Medvedev

V. E.

к.м.н., заведующий кафедрой психиатрии, психотерапии и психосоматической патологии Медицинского института Российского университета дружбы народов им.Патриса Лумумбы

Москва, Россия

PhD, Head of the Department of Psychiatry, Psychotherapy and Psychosomatic Pathology

Moscow, Russia

Мосолов

С. Н.

Mosolov

S. N.

д.м.н., профессор, заведующий кафедрой психиатрии Российской медицинской академии непрерывного профессионального образования

Москва, Россия

MD, Professor, Head of the Department of Psychiatry

Moscow, Russia

Петрова

М. М.

Petrova

M. M.

д.м.н., профессор, заведующий кафедрой поликлинической терапии и семейной медицины Красноярского государственного медицинского университета имени профессора В.Ф. Войно-Ясенецкого

Красноярск, Россия

MD, Professor, Head of the Department of Polyclinic Therapy and Family Medicine

Krasnoyarsk, Russia

Петрунько

О. В.

Petrunko

O. V.

к.м.н., заведующий кафедрой психиатрии и наркологии Иркутской государственной медицинской академии последипломного образования

Москва, Россия

PhD, Head of the Department of Psychiatry and Narcology

Moscow, Russia

Попонина

Т. М.

Poponina

T. M.

д.м.н., профессор кафедры кардиологии Сибирского государственного медицинского университета

Томск, Россия

MD, Professor, Departments of Cardiology

Tomsk, Russia

Репин

А. Н.

Repin

A. N.

д.м.н., профессор, руководитель отделения амбулаторной кардиологии Научно-исследовательского института кардиологии Томского национального исследовательского медицинского центра Российской академии наук

Томск, Россия

MD, Professor, Head of the Outpatient Cardiology Department

Tomsk, Russia

Собенников

В. С.

Sobennikov

V. S.

д.м.н., профессор, заведующий кафедрой психиатрии и медицинской психологии Иркутского государственного медицинского университета

Иркутск, Россия

MD, Professor, Head of the Department of Psychiatry

Irkutsk, Russia

Сумин

А. Н.

Sumin

A. N.

д.м.н., заведующий лабораторией коморбидности при сердечно-сосудистых заболеваниях Научно-исследовательского института комплексных проблем сердечно-сосудистых заболеваний

Кемерово, Россия

MD, Head of the Laboratory of Comorbidity in Cardiovascular Diseases

Kemerovo, Russia

ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РФРоссияRussian Medical Academy of Continuing Professional EducationRussian Federation

ФГБОУ ВО «Российский национальный исследовательский медицинский университет имени Н. И. Пирогова» Минздрава РФРоссияPirogov Russian National Research Medical UniversityRussian Federation

ФГАОУ ВО «Первый Московский государственный медицинский университет имени И. М. Сеченова» Минздрава РФ, (Сеченовский университет)РоссияSechenov First Moscow State Medical UniversityRussian Federation

ФГБОУ ВО «Сибирский государственный медицинский университет» Минздрава РФРоссияSiberian State Medical UniversityRussian Federation

ФГБОУ ВО «Читинская государственная медицинская академии» Минздрава РФРоссияChita State Medical AcademyRussian Federation

ФГБОУ ВО «Российский университет дружбы народов имени Патриса Лумумбы»РоссияPatrice Lumumba Peoples’ Friendship University of RussiaRussian Federation

ФГБОУ ВО «Красноярский государственный медицинский университет имени профессора В.Ф. Войно-Ясенецкого» Минздрава РФРоссияVoyno-Yasenetsky Krasnoyarsk State Medical UniversityRussian Federation

ФГБНУ «Томский национальный исследовательский медицинский центр» Российской академии наукРоссияTomsk National Research Medical Center of the Russian Academy of SciencesRussian Federation

ФГБОУ ВО «Иркутский государственный медицинский университет» Минздрава РФРоссияIrkutsk State Medical UniversityRussian Federation

ФГБНУ «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний»РоссияResearch Institute for Complex Issues of Cardiovascular DiseasesRussian Federation

2025

07072025

6565473

2025

Kardiomag

https://cardio.elpub.ru/jour/about/submissions#copyrightNotice

https://cardio.elpub.ru/jour/article/view/2921

Эксперты рабочих групп Российского кардиологического общества и Российского общества психиатров, Байкальской и Сибирской психосоматических ассоциаций разработали рекомендации по диагностике и лечению распространенных психических расстройств у пациентов с сердечно-сосудистыми заболеваниями. Положения документа основаны на результатах наиболее надежных научных исследований и рекомендациях авторитетных медицинских обществ, призваны информировать врачей о надлежащей клинической практике. Настоящий документ отражает позицию профессиональных организаций по актуальной междисциплинарной проблеме. Согласованный документ ориентирован на кардиологов, врачей общей практики, психиатров и врачей других специальностей, оказывающих помощь пациентам с сердечно-сосудистыми заболеваниями и коморбидными психическими расстройствами.

Experts of the working groups of the Russian Society of Cardiology and the Russian Society of Psychiatrists, the Baikal and Siberian Psychosomatic Associations have developed guidelines on the diagnosis and treatment of common mental disorders in patients with cardiovascular diseases. The provisions of the document are based on the results of the most reliable scientific research and recommendations of authoritative medical societies, and are intended to inform physicians about good clinical practice. This document reflects the position of professional organizations on a relevant interdisciplinary problem.The agreed document is intended for cardiologists, general practitioners, psychiatrists, and other medical specialists who provide care to patients with cardiovascular diseases and comorbid mental disorders.

Посттравматическое стрессовое расстройствотревожное расстройстводепрессивное расстройствокогнитивные нарушенияартериальная гипертензияинфаркт миокардаишемическая болезнь сердцафибрилляция предсердийвнезапная сердечная смертьсердечная недостаточность

Post-traumatic stress disorderanxiety disorderdepressive disordercognitive disordersarterial hypertensionmyocardial infarctionischemic heart diseaseatrial fibrillationsudden cardiac deathheart failure

Конфликт интересов не заявлен

No conflict of interest is reported.

References1

World Health Organization. Mental мHealth Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders. - Geneva: World Health Organization; 2023. - 152p. ISBN 978 92-4-008427-8

Байкальская психосоматическая ассоциация. Клинические рекомендации по психосоматической медицине. – Иркутск; 2024. - 36с. Доступно на: https://therapy.irkutsk.ru/ispm/psomatic6.pdf

Baikal Psychosomatic Association. Clinical guidelines for psychosomatic medicine. - Irkutsk; 2024. - 36p. https://therapy.irkutsk.ru/ispm/psomatic6.pdf

Белялов Ф.И., Сумин А.Н., Гарганеева Н.П., Ларева Н.В., Петрова М.М., Петрунь ко О.В. и др. Психические расстройства и сердечно-сосудистые болезни: клинические рекомендации Байкальской психосоматической ассоциации и Сибирской психосоматической ассоциации. Комплексные проблемы сердечно-сосудистых заболеваний. 2024;13(3S):222-53. DOI: 10.17802/2306-1278-2024-13 3S-222-253

Belialov F.I., Sumin A.N., Garganeeva N.P., Lareva N.V., Petrova M.M., Petrunko O.V. et al. Mental disorders and cardiovascular dis eases: guidelines of the Baikal Psychosomatic Association and the Siberian Psychosomatic Association. Complex Issues of Cardiovascular Diseases. 2024;13(3S):222–53. DOI: 10.17802/2306-1278-2024-13 3S-222-253

Бойцов С.А., Погосова Н.В., Аншелес А.А., Бадтиева В.А., Балахонова Т.В., Барбараш О.Л. и др. Кардиоваскулярная профилактика 2022. Российские национальные рекомендации. Российский кардиологический журнал. 2023;28(5):119-249. DOI: 10.15829/1560-4071-2023-5452

Boytsov S.A., Pogosova N.V., Ansheles A.A., Badtieva V.A., Balakhonova T.V., Barbarash O.L. et al. Cardiovascular prevention 2022. Russian national guidelines. Russian Journal of Cardiology. 2023;28(5):119–249. DOI: 10.15829/1560-4071-2023-5452

Министерство здравоохранения Российской Федерации. Российское общество психиатров. Депрессивный эпизод, рекуррентное депрессивное расстройство. 2024. 125с. Доступно на: https://cr.minzdrav.gov.ru/view-cr/301_3

Ministry of Health of the Russian Federation. Russian Society of Psychiatrists. Depressive episode, recurrent depressive disorder. 2024. 125p. Av. at: https://cr.minzdrav.gov.ru/view-cr/301_3

Министерство здравоохранения Российской Федерации. Российское общество психиатров. Генерализованное тревожное расстройство. 2024. 121с. Доступно на: https://cr.minzdrav.gov.ru/view-cr/457_3

Ministry of Health of the Russian Federation. Russian Society of Psychiatrists. Generalized anxiety disorder. 2024. 121p. Av. at: https:// cr.minzdrav.gov.ru/view-cr/457_3

Министерство здравоохранения Российской Федерации. Российское общество психиатров. Паническое расстройство. 2024. 140с. Доступно на: https://cr.minzdrav.gov.ru/view-cr/456_3

Ministry of Health of the Russian Federation. Russian Society of Psychiatrists. Panic disorder. 2024. 140p. Av. at: https://cr.minzdrav.gov.ru/view-cr/456_3

Министерство здравоохранения Российской Федерации. Российское общество психиатров. Посттравматическое стрессовое расстройство. 2023. 200c. Доступно на: https://cr.minzdrav.gov.ru/preview-cr/753_1

Ministry of Health of the Russian Federation. Russian Society of Psychiatrists. Posttraumatic stress disorder. 2023. 200p. Av. at: https://cr.minzdrav.gov.ru/preview-cr/753_1

Министерство здравоохранения Российской Федерации. Российское общество психиатров, Российская ассоциация геронтологов и гериатров. Когнитивные расстройства у лиц пожилого и старческого возраста. 2020. 239с. https://rgnkc.ru/fp-starshee-pokolenie/geriatricheskaya-pomosch/normativno-pravovaya-baza/5/2.pdf

Ministry of Health of the Russian Federation. Russian Society of Psychiatrists, Russian Association of Gerontologists and Geriatrists. Cognitive disorders in the elderly and senile. 2020. 239p. Av. at: https://rgnkc.ru/fp-starshee-pokolenie/geriatricheskaya-pomosch/normativno-pravovaya-baza/5/2.pdf

Albus C, Waller C, Fritzsche K, Gunold H, Haass M, Hamann B et al. Significance of psycho-social factors in cardiology: update 2018: Position paper of the German Cardiac Society. Clinical Research in Cardiology. 2019;108(11):1175–96. DOI: 10.1007/s00392-019-01488-w

American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder. Third Edition. 2010. 152p. Av. at: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf

Colquhoun DM, Bunker SJ, Clarke DM, Glozier N, Hare DL, Hickie IB et al. Screening, referral and treatment for depression in patients with coronary heart disease. Medical Journal of Australia. 2013;198(9):483–4. DOI: 10.5694/mja13.10153

Frost JL, Rich RL, Robbins CW, Stevermer JJ, Chow RT, Leon KK et al. Depression Following Acute Coronary Syndrome Events: Screening and Treatment Guidelines from the AAFP. Av. at: https://www.aafp.org/pubs/afp/issues/2019/0615/od2.pdf. American Family Physician. 2019;99(12). PMID: 31194478

Ladwig KH, Baghai TC, Doyle F, Hamer M, Herrmann-Lingen C, Kunschitz E et al. Mental healthrelated risk factors and interventions in patients with heart failure: a position paper endorsed by the European Association of Preventive Cardiology (EAPC). European Journal of Preventive Cardiology. 2022;29(7):1124–41. DOI: 10.1093/eurjpc/zwac006

Lichtman JH, Froelicher ES, Blumenthal JA, Carney RM, Doering LV, Frasure-Smith N et al. Depression as a Risk Factor for Poor Prognosis Among Patients With Acute Coronary Syndrome: Systematic Review and Recommendations: A Scientific Statement From the American Heart Association. Circulation. 2014;129(12):1350–69. DOI: 10.1161/CIR.0000000000000019

Lichtman JH, Bigger JT, Blumenthal JA, Frasure-Smith N, Kaufmann PG, Lesperance F et al. Depression and Coronary Heart Disease: Recommendations for Screening, Referral, and Treatment: A Science Advisory From the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: Endorsed by the American Psychiatric Association. Circulation. 2008;118(17):1768–75. DOI: 10.1161/CIRCULATIONAHA.108.190769

Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021;42(34):3227–337. DOI: 10.1093/eurheartj/ehab484

Vaccarino V, Badimon L, Bremner JD, Cenko E, Cubedo J, Dorobantu M et al. Depression and coronary heart disease: 2018 position paper of the ESC working group on coronary pathophysiology and microcirculation. European Heart Journal. 2020;41(17):1687–96. DOI: 10.1093/eurheartj/ehy913

Александровский Ю.А., Незнанов Н.Г. Психиатрия. Национальное руководство. – М.: ГЭОТАР-Медиа; 2022. - 1008с. ISBN 978-5-9704-7334-4

Alexandrovsky Yu.A., Neznanov N.G. Psychiatry. National textbook. - M.: GEOTAR-Media; 2022. - 1008p. ISBN 978-5-9704-7334-4

Roberts LW. The American Psychiatric Association Publishing textbook of psychiatry. - Washington, D.C: American Psychiatric Association Publishing; 2019. - 1362 p. ISBN 978-1-61537-256-0

Boland RJ, Verduin ML, Ruiz P, Shah A, Sadock BJ. Kaplan & Sadock’s synopsis of psychiatry. - Philadelphia: Wolters Kluwer; 2022. - 1173p. ISBN 978-1-975145-56-9

Levenson JL. The American Psychiatric Association Publishing textbook of psychosomatic medicine and consultationliaison psychiatry. - Washington, D.C: American Psychiatric Association Publishing; 2019. - 1561p. ISBN 978-1-61537-136-5

Лебедева Е.В., Нонка Т.Г., Репин А.Н., Шишнева Е.В., Счастный Е.Д., Симуткин Г.Г. и др. Современная психокардиология. – Томск: ООО Интегральный переплет; 2019. - 160с. ISBN 978-5-604-14671-2

Lebedeva E.V., Nonka T.G., Repin A.N., Shishneva E.V., Schastnyi E.D., Simutkin G.G. et al. Modern psychocardiology. - Tomsk: Integral Binding LLC; 2019. - 160p. ISBN 978-5-604-14671-2

Волель Б.А., Петелин Д.С., Романов Д.В., Воронова Е.И., Копылов Ф.Ю., Бекетов В.Д. Алгоритмы диагностики и терапии психических расстройств в общемедицинской практике. Учебное пособие. - М.: Издательство МАИ, 2020. - 78с. ISBN 978-5-4316-0765-3

Volel B.A., Petelin D.S., Romanov D.V., Voronova E.I., Kopylov F.Yu., Beketov V.D. Algorithms for the diagnosis and therapy of mental disorders in general medical practice. Training manual. - M.: MAI Publishing House; 2020. - 78p. ISBN 978-5-4316-0765-3

Смулевич А.Б. Психосоматические расстройства. Руководство для практических врачей. 2-е изд. - М: МЕДпресс-информ; 2019. - 496с. ISBN 978-5-00030-778-6

Smulevich A.B. Psychosomatic disorders. A guide for practitioners. 2nd edition. - M.: MEDpressinform; 2019. - 496p. ISBN 978-5-00030-778-6

Белялов Ф.И. Психосоматика. 10-е изд. - М.: ГЭОТАР-Медиа; 2025. - 452c. ISBN 978-5-9704-9004-4

Belialov F.I. Psychosomatics. 10th edition. - M.: GEOTAR-Media; 2025. - 452p. ISBN 978-5-9704-9004-4

Медведев В.Э. Депресcивные расстройства. В кн.: Путеводитель врачебных назначений. Современное руководство для практикующих врачей. Том 6. C.57-69. – М.: Бионика Медиа; 2018. ISBN 978-5-906444-09-7

Medvedev V.E. Depressive disorders. In: A guide to medical appointments. A modern guide for practicing physicians. Vol. 6. P.57-69. – M.: Bionica Media; 2018. ISBN 978-5-906444-09-7

МКБ-11. Глава 06. Психические и поведенческие расстройства и нарушения нейропсихического развития. Статистическая классификация. – М.: КДУ, Университетская книга; 2021. - 432с. DOI: 10.31453/kdu.ru.91304.0143. ISBN 978-5-91304-954-4

Kostyuk G.P. ICD-11. Chapter 06. Mental and behavioral disorders and neuropsychiatric developmental disorders. Statistical classification. - M.: KDU, University book; 2021. - 432p. ISBN 978-5-91304-954-4

World Health Organization. Clinical Descriptions and Diagnostic Requirements for ICD-11 Mental, Behavioural and Neurodevelopmental Disorders. - Geneva: WHO; 2024. - 852p. ISBN 978-92-4-007726-3

Stein DJ, Szatmari P, Gaebel W, Berk M, Vieta E, Maj M et al. Mental, behavioral and neuro-developmental disorders in the ICD-11: an international perspective on key changes and controversies. BMC Medicine. 2020;18(1):21. DOI: 10.1186/s12916-020-1495-2

Levis B, Benedetti A, Riehm KE, Saadat N, Levis AW, Azar M et al. Probability of major depression diagnostic classification using semistructured versus fully structured diagnostic interviews. The British Journal of Psychiatry. 2018;212(6):377–85. DOI: 10.1192/bjp.2018.54

Kwapong YA, Boakye E, Khan SS, Honigberg MC, Martin SS, Oyeka CP et al. Association of Depression and Poor Mental Health With Cardiovascular Disease and Suboptimal Cardiovascular Health Among Young Adults in the United States. Journal of the American Heart Association. 2023;12(3):e028332. DOI: 10.1161/JAHA.122.028332

Bojanić I, Sund ER, Sletvold H, Bjerkeset O. Prevalence trends of depression and anxiety symptoms in adults with cardiovascular diseases and diabetes 1995–2019: The HUNT studies, Norway. BMC Psychology. 2021;9(1):130. DOI: 10.1186/s40359-021-00636-0

Погосова Н.В., Бойцов С.А., Оганов Р.Г., Юферева Ю.М., Костюк Г.П., Курсаков А.А. и др. Клинико-эпидемиОлогическая програМма изучЕния психосоциальных факТоров рискА в кардиологической практике у больных артериальной гипертонией и ишемической болезнью сердца (КОМЕТА): первые результаты российского многоцентрового исследования. Кардиология. 2018;58(9):47–58. DOI: 10.18087/cardio.2018.9.10171

Pogosova N.V., Boytsov S.A., Oganov R.G., Yufereva Yu.M., Kostyuk G.P., Kursakov A.A. et al. Clinical-Epidemiological Program of Studying Psychosocial Risk Factors in Cardiological Practice in Patients With Arterial Hypertension and Ischemic Heart Disease: First Results of a Multicenter Study in Russia. Kardiologiia. 2018;58(9):47–58. DOI: 10.18087/cardio.2018.9.10171

Karami N, Kazeminia M, Karami A, Salimi Y, Ziapour A, Janjani P. Global prevalence of depression, anxiety, and stress in cardiac patients: A systematic review and meta-analysis. Journal of Affective Disorders. 2023;324:175–89. DOI: 10.1016/j.jad.2022.12.055

Gaffey AE, Gathright EC, Fletcher LM, Goldstein CM. Screening for Psychological Distress and Risk of Cardiovascular Disease and Related Mortality: A Systematized Review, Meta-analysis, and Case for Prevention. Journal of Cardiopulmonary Rehabilitation and Prevention. 2022;42(6):404–15. DOI: 10.1097/HCR.0000000000000751

Nakamura S, Kato K, Yoshida A, Fukuma N, Okumura Y, Ito H et al. Prognostic Value of Depression, Anxiety, and Anger in Hospitalized Cardiovascular Disease Patients for Predicting Adverse Cardiac Outcomes. The American Journal of Cardiology. 2013;111(10):1432–6. DOI: 10.1016/j.amjcard.2013.01.293

Fan AZ, Strine TW, Jiles R, Berry JT, Mokdad AH. Psychological distress, use of rehabilitation services, and disability status among noninstitutionalized US adults aged 35 years and older, who have cardiovascular conditions, 2007. International Journal of Public Health. 2009;54(Suppl 1):100–5. DOI: 10.1007/s00038-009-1313-2

Charlson FJ, Moran AE, Freedman G, Norman RE, Stapelberg NJ, Baxter AJ et al. The contribution of major depression to the global burden of ischemic heart disease: a comparative risk assessment. BMC Medicine. 2013;11(1):250. DOI: 10.1186/1741-7015-11-250

Bekelman DB, Havranek EP, Becker DM, Kutner JS, Peterson PN, Wittstein IS et al. Symptoms, Depression, and Quality of Life in Patients With Heart Failure. Journal of Cardiac Failure. 2007;13(8):643–8. DOI: 10.1016/j.cardfail.2007.05.005

Gravely-Witte S, De Gucht V, Heiser W, Grace SL, Van Elderen T. The impact of angina and cardiac history on health-related quality of life and depression in coronary heart disease patients. Chronic Illness. 2007;3(1):66–76. DOI: 10.1177/1742395307079192

Huang W, Aune D, Ferrari G, Zhang L, Lan Y, Nie J et al. Psychological Distress and All-Cause, Cardiovascular Disease, Cancer Mortality Among Adults with and without Diabetes. Clinical Epidemiology. 2021;13:555–65. DOI: 10.2147/CLEP.S308220

Meier SM, Mattheisen M, Mors O, Mortensen PB, Laursen TM, Penninx BW. Increased mortality among people with anxiety disorders: total population study. British Journal of Psychiatry. 2016;209(3):216–21. DOI: 10.1192/bjp.bp.115.171975

Meier SM, Mattheisen M, Mors O, Mortensen PB, Laursen TM, Penninx BW. Increased mor-tality among people with anxiety disorders: total population study. British Journal of Psychiatry. 2016;209(3):216–21. DOI: 10.1192/bjp.bp.115.171975

Zhang Z, Jackson SL, Gillespie C, Merritt R, Yang Q. Depressive Symptoms and Mortality Among US Adults. JAMA Network Open. 2023;6(10):e2337011. DOI: 10.1001/jamanetworkopen.2023.37011

Péquignot R, Dufouil C, Pérès K, Artero S, Tzourio C, Empana J. Depression Increases the Risk of Death Independently From Vascular Events in Elderly Individuals: The Three‐City Study. Journal of the American Geriatrics Society. 2019;67(3):546–52. DOI: 10.1111/jgs.15731

Shen R, Zhao N, Wang J, Guo P, Shen S, Liu D et al. Association between level of depression and coronary heart disease, stroke risk and all-cause and cardiovascular mortality: Data from the 2005–2018 National Health and Nutrition Examination Survey. Frontiers in Cardiovascular Medicine. 2022;9:954563. DOI: 10.3389/fcvm.2022.954563

Tian F, Shen Q, Hu Y, Ye W, Valdimarsdóttir UA, Song H et al. Association of stress-related disorders with subsequent risk of all-cause and cause-specific mortality: A population-based and sibling-controlled cohort study. The Lancet Regional Health - Europe. 2022;18:100402. DOI: 10.1016/j.lanepe.2022.100402

Mourad G, Lundgren J, Andersson G, Johansson P. Healthcare use in patients with cardiovascular disease and depressive symptoms – The impact of a nurseled internet-delivered cognitive behavioural therapy program. A secondary analysis of a RCT. Internet Interventions. 2024;35:100696. DOI: 10.1016/j.invent.2023.100696

Mourad G, Jaarsma T, Hallert C, Strömberg A. Depressive symptoms and healthcare utilization in patients with noncardiac chest pain compared to patients with ischemic heart disease. Heart & Lung. 2012;41(5):446–55. DOI: 10.1016/j.hrtlng.2012.04.002

Ni J, Yan Y, Du W, Tian Y, Fan L. Depressive symptoms, alone or together with physical comorbidity, are predictive of healthcare use and spending in older adults. Journal of Psychosomatic Research. 2023;174:111482. DOI: 10.1016/j.jpsychores.2023.111482

Stephenson JJ, Grabner M, Faries D, Palli SR, Robinson R. The impact of anxiety on Healthcare Utilization and costs among respondents from the Co-Morbidities and Symptoms of depression (CODE) study. Value in Health. 2015;18(3):A119. DOI: 10.1016/j.jval.2015.03.700

Horenstein A, Heimberg RG. Anxiety disorders and healthcare utilization: A systematic review. Clinical Psychology Review. 2020;81:101894. DOI: 10.1016/j.cpr.2020.101894

Seldenrijk A, Vogelzangs N, Batelaan NM, Wieman I, Van Schaik DJF, Penninx BJWH. Depression, anxiety and 6-year risk of cardiovascular disease. Journal of Psychosomatic Research. 2015;78(2):123–9. DOI: 10.1016/j.jpsychores.2014.10.007

Curth NK, Hjorthøj C, Brinck-Claussen U, Jørgensen KB, Rosendal S, Bojesen AB et al. The effects of collaborative care versus consultation liaison for anxiety disorders and depression in Denmark: two randomised controlled trials. The British Journal of Psychiatry. 2023;223(3):430–7. DOI: 10.1192/bjp.2023.77

Sighinolfi C, Nespeca C, Menchetti M, Levantesi P, Belvederi Murri M, Berardi D. Collaborative care for depression in European countries: A systematic review and meta-analysis. Journal of Psychosomatic Research. 2014;77(4):247–63. DOI: 10.1016/j.jpsychores.2014.08.006

Huffman JC, Mastromauro CA, Beach SR, Celano CM, DuBois CM, Healy BC et al. Collaborative Care for Depression and Anxiety Disorders in Patients With Recent Cardiac Events: The Management of Sadness and Anxiety in Cardiology (MOSAIC) Randomized Clinical Trial. JAMA Internal Medicine. 2014;174(6):927–36. DOI: 10.1001/jamainternmed.2014.739

Camacho EM, Ntais D, Coventry P, Bower P, Lovell K, Chew-Graham C et al. Long-term cost-effectiveness of collaborative care (vs usual care) for people with depression and comorbid diabetes or cardiovascular disease: a Markov model informed by the COINCIDE randomised controlled trial. BMJ Open. 2016;6(10):e012514. DOI: 10.1136/bmjopen-2016-012514

Richards DA, Bower P, Chew-Graham C, Gask L, Lovell K, Cape J et al. Clinical effectiveness and cost-effectiveness of collaborative care for depression in UK primary care (CADET): a cluster randomised controlled trial. Health Technology Assessment. 2016;20(14):1–192. DOI: 10.3310/hta20140

Краснов В.Н., Вельтищев Д.Ю., Бобров А.Е., Довженко Т.В. Расстройства аффективного спектра в общей медицинской практике (принципы терапии и партнерского взаимодействия психиатров и интернистов). Методические рекомендации. - М.: Национальный медицинский исследовательский центр психиатрии и наркологии имени В.П. Сербского; 2021. - 32с. ISBN 978-5-86002-303-1

Krasnov V.N., Veltischev D.Yu., Bobrov A.E., Dovzhenko T.V. Affective spectrum disorders in general medical practice (principles of therapy and partnership between psychiatrists and internists). Methodological recommendations. - M.: V.P. Serbsky National Medical Research Center of Psychiatry and Narcology; 2021. - 32p. ISBN 978-5-86002-303-1

Silverman JJ, Galanter M, Jackson-Triche M, Jacobs DG, Lomax JW, Riba MB et al. The American Psychiatric Association Practice Guidelines for the Psychiatric Evaluation of Adults. American Journal of Psychiatry. 2015;172(8):798–802. DOI: 10.1176/appi.ajp.2015.1720501

Correll CU, Galling B, Pawar A, Krivko A, Bonetto C, Ruggeri M et al. Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis: A Systematic Review, Meta-analysis, and Metaregression. JAMA Psychiatry. 2018;75(6):555–65. DOI: 10.1001/jamapsychiatry.2018.0623

Albert N, Melau M, Jensen H, Emborg C, Jepsen JRM, Fagerlund B et al. Five years of specialised early intervention versus two years of specialised early intervention followed by three years of standard treatment for patients with a first episode psychosis: randomised, superiority, parallel group trial in Denmark (OPUS II). BMJ. 2017;356:i6681. DOI: 10.1136/bmj.i6681

Fernández A, Pinto-Meza A, Bellón JA, Roura-Poch P, Haro JM, Autonell J et al. Is major depression adequately diagnosed and treated by general practitioners? Results from an epidemiological study. General Hospital Psychiatry. 2010;32(2):201–9. DOI: 10.1016/j.genhosppsych.2009.11.015

Siskind D, Araya R, Kim J. Cost-effectiveness of improved primary care treatment of depression in women in Chile. British Journal of Psychiatry. 2010;197(4):291–6. DOI: 10.1192/bjp.bp.109.068957

Katon W, Rutter C, Ludman EJ, Von Korff M, Lin E, Simon G et al. A Randomized Trial of Relapse Prevention of Depression in Primary Care. Archives of General Psychiatry. 2001;58(3):241–7. DOI: 10.1001/archpsyc.58.3.241

Trautman S, Beesdo-Baum K. The Treatment of Depression in Primary Care. Deutsches Ärzteblatt international. 2017;114(43):721–8. DOI: 10.3238/arztebl.2017.0721

Weisberg RB, Dyck I, Culpepper L, Keller MB. Psychiatric Treatment in Primary Care Patients With Anxiety Disorders: A Comparison of Care Received From Primary Care Providers and Psychiatrists. American Journal of Psychiatry. 2007;164(2):276–82. DOI: 10.1176/ajp.2007.164.2.276

Parker EL, Banfield M, Fassnacht DB, Hatfield T, Kyrios M. Contemporary treatment of anxiety in primary care: a systematic review and metaanalysis of outcomes in countries with universal healthcare. BMC Family Practice. 2021;22(1):92. DOI: 10.1186/s12875-021-01445-5

Bruce ML, Raue PJ, Reilly CF, Greenberg RL, Meyers BS, Banerjee S et al. Clinical Effectiveness of Integrating Depression Care Management Into Medicare Home Health: The Depression CAREPATH Randomized Trial. JAMA Internal Medicine. 2015;175(1):55–64. DOI: 10.1001/jamainternmed.2014.5835

Лебедева Е.В., Репин А.Н., Счастный Е.Д., Сергиенко Т.Н., Симуткин Г.Г., Горохов А.С. и др. Методическое пособие по организации работы междисциплинарной команды при реабилитации пациентов с хронической ишемической болезнью сердца и депрессивными расстройствами. – Томск: Иван Федоров; 2015. - 106с. ISBN 978-5-91701-104-2

Lebedeva E.V., Repin A.N., Schastny E.D., Sergienko T.N., Simutkin G.G., Gorokhov A.S. et al. A methodological guide for organizing the work of an interdisciplinary team in the rehabilitation of patients with chronic coronary heart disease and depressive disorders. - Tomsk: Ivan Fedorov; 2015. - 106p. ISBN 978-5-91701-104-2

Li M, Tang H, Liu X. Primary care team and its association with quality of care for people with multimorbidity: a systematic review. BMC Primary Care. 2023;24(1):20. DOI: 10.1186/s12875-023-01968-z

Chen JA, Macchiano S, Beckmann D, Chung W-J, Gartaganis S, Huffman JC. Implementing Multidisciplinary, Team-Based Care in an Academic Outpatient Psychiatry Department. Psychiatric Services. 2022;73(11):1290–3. DOI: 10.1176/appi.ps.202200030

Olfson M, Blanco C, Marcus SC. Treatment of Adult Depression in the United States. JAMA Internal Medicine. 2016;176(10):1482–91. DOI: 10.1001/jamainternmed.2016.5057

Jha MK, Qamar A, Vaduganathan M, Charney DS, Murrough JW. Screening and Management of Depression in Patients With Cardiovascular Disease: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2019;73(14):1827–45. DOI: 10.1016/j.jacc.2019.01.041

US Preventive Services Task Force, Barry MJ, Nicholson WK, Silverstein M, Chelmow D, Coker TR et al. Screening for Depression and Suicide Risk in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2023;329(23):2057–67. DOI: 10.1001/jama.2023.9297

US Preventive Services Task Force, Barry MJ, Nicholson WK, Silverstein M, Coker TR, Davidson KW et al. Screening for Anxiety Disorders in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2023;329(24):2163–70. DOI: 10.1001/jama.2023.9301

Золотарева А.А. Адаптация русскоязычной версии шкалы генерализованного тревожного расстройства (Generalized Anxiety Disorder-7). Консультативная психология и психотерапия. 2023;31(4):31–46. DOI: 10.17759/cpp.2023310402

Zolotareva A.A. Adaptation of the Russian version of the Generalized Anxiety Disorder-7. Counseling Psychology and Psychotherapy. 2023;31(4):31–46. DOI: 10.17759/cpp.2023310402

Погосова Н.В., Довженко Т.В., Бабин А.Г., Курсаков А.А., Выгодин В.А. Русскоязычная версия опросников PHQ-2 и 9: чувствительность и специфичность при выявлении депрессии у пациентов общемедицинской амбулаторной практики. Кардиоваскулярная терапия и профилактика. 2014;13(3):18-24. DOI: 10.15829/1728-8800-2014-3-18-24

Pogosova N.V., Dovzhenko T.V., Babin A.G., Kursakov A.A., Vygodin V.A. Russian version of PHQ-2 and 9 Questionnaires: sensitivity and specificity in detection of depression in outpatient general medical practice. Cardiovascular Therapy and Prevention. 2014;13(3):18–24. DOI: 10.15829/1728-8800-2014-3-18-24

Морозова М.А., Потанин С.С., Бениашвили А.Г., Бурминский Д.С., Лепилкина Т.А., Рупчев Г.Е. и др. Валидация русскоязычной версии Госпитальной шкалы тревоги и депрессии в общей популяции. Профилактическая медицина. 2023;26(4):7-14. DOI: 10.17116/profmed2023260417

Morozova M.A., Potanin S.S., Beniashvili A.G., Burminsky D.S., Lepilkina T.A., Rupchev G.E. et al. Validation of the Hospital Anxiety and Depression Scale Russian-language version in the general population. Russian Journal of Preventive Medicine. 2023;26(4):7–14. DOI: 10.17116/profmed2023260417

Irwing P, Booth T, Hughes DJ. The Wiley handbook of psychometric testing: a multidisciplinary reference on survey, scale and test development. - Hoboken (N.J.): Wiley Blackwell; 2018. - 1022p. ISBN 978-1-118-48977-2

Белялов Ф.И. Прогнозирование и шкалы в медицине. 4-е изд. – М.: ГЭОТАР-Медиа; 2023. - 416с. ISBN 978-5-9704-7307-8

Belialov F.I. Prognosis and scores in medicine. 4th edition. - M.: GEOTAR-Media; 2023. - 416p. ISBN 978-5-9704-7307-8

Wu Y, Levis B, Sun Y, He C, Krishnan A, Neupane D et al. Accuracy of the Hospital Anxiety and Depression Scale Depression subscale (HADS-D) to screen for major depression: systematic review and individual participant data meta-analysis. BMJ. 2021;373:n972. DOI: 10.1136/bmj.n972

Levis B, Benedetti A, Thombs BD. Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis. BMJ. 2019;365:l1476. DOI: 10.1136/bmj.l1476

Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic meta-analysis. General Hospital Psychiatry. 2016;39:24–31. DOI: 10.1016/j.genhosppsych.2015.11.005

Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. General Hospital Psychiatry. 2016;39:24–31. DOI: 10.1016/j.genhosppsych.2015.11.005

Manea L, Gilbody S, McMillan D. A diagnostic meta-analysis of the Patient Health Question-naire-9 (PHQ-9) algorithm scoring method as a screen for depression. General Hospital Psychiatry. 2015;37(1):67–75. DOI: 10.1016/j.genhosppsych.2014.09.009

Christensen AV, Dixon JK, Juel K, Ekholm O, Rasmussen TB, Borregaard B et al. Psychometric properties of the Danish Hospital Anxiety and Depression Scale in patients with cardiac disease: results from the DenHeart survey. Health and Quality of Life Outcomes. 2020;18(1):9. DOI: 10.1186/s12955-019-1264-0

Thombs BD, Ziegelstein RC, Roseman M, Kloda LA, Ioannidis JP. There are no randomized controlled trials that support the United States Preventive Services Task Force guideline on screening for depression in primary care: a systematic review. BMC Medicine. 2014;12(1):13. DOI: 10.1186/1741-7015-12-13

Romera I, Montejo ÁL, Aragonés E, Arbesú JÁ, Iglesias-García C, López S et al. Systematic depression screening in high-risk patients attending primary care: a pragmatic cluster-randomized trial. BMC Psychiatry. 2013;13(1):83. DOI: 10.1186/1471-244X-13-83

Moore M, Ali S, Stuart B, Leydon GM, Ovens J, Goodall C et al. Depression management in primary care: an observational study of management changes related to PHQ-9 score for depression monitoring. British Journal of General Practice. 2012;62(599):e451–7. DOI: 10.3399/bjgp12X649151

Toussaint A, Hüsing P, Gumz A, Wingenfeld K, Härter M, Schramm E et al. Sensitivity to change and minimal clinically important difference of the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7). Journal of Affective Disorders. 2020;265:395–401. DOI: 10.1016/j.jad.2020.01.032

Murphy B, Le Grande M, Alvarenga M, Worcester M, Jackson A. Anxiety and Depression After a Cardiac Event: Prevalence and Predictors. Frontiers in Psychology. 2020;10:3010. DOI: 10.3389/fpsyg.2019.03010

O’Connor EA, Henninger ML, Perdue LA, Coppola EL, Thomas RG, Gaynes BN. Anxiety Screening: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2023;329(24):2171–84. DOI: 10.1001/jama.2023.6369

Nimalasuriya K, Compton MT, Guillory VJ, Prevention Practice Committee of the American College of Preventive Medicine. Screening adults for depression in primary care: A position statement of the American College of Preventive Medicine. The Journal of Family Practice. 2009;58(10):535–8. PMID: 19874732

ICSI. Major Depression in Adults in Primary Care. 17th edition. 2016. 131p. Av. at: https://www.icsi.org/wp-content/uploads/2021/11/DeprES.pdf.

Adzrago D, Walker TJ, Williams F. Reliability and validity of the Patient Health Question-naire-4 scale and its subscales of depression and anxiety among US adults based on nativity. BMC Psychiatry. 2024;24(1):213. DOI: 10.1186/s12888-024-05665-8

Reavell J, Hopkinson M, Clarkesmith D, Lane DA. Effectiveness of Cognitive Behavioral Therapy for Depression and Anxiety in Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis. Psychosomatic Medicine. 2018;80(8):742–53. DOI: 10.1097/PSY.0000000000000626

Holdgaard A, Eckhardt-Hansen C, Lassen CF, Kjesbu IE, Dall CH, Michaelsen KL et al. Cognitive-behavioural therapy reduces psychological distress in younger patients with cardiac disease: a randomized trial. European Heart Journal. 2023;44(11):986–96. DOI: 10.1093/eurheartj/ehac792

El Baou C, Desai R, Cooper C, Marchant NL, Pilling S, Richards M et al. Psychological therapies for depression and cardiovascular risk: evidence from national healthcare records in England. European Heart Journal. 2023;44(18):1650–62. DOI: 10.1093/eurheartj/ehad188

Cuijpers P, Miguel C, Harrer M, Plessen CY, Ciharova M, Ebert D et al. Cognitive behavior therapy vs. control conditions, other psychotherapies, pharmacotherapies and combined treatment for depression: a comprehensive meta‐analysis including 409 trials with 52,702 patients. World Psychiatry. 2023;22(1):105–15. DOI: 10.1002/wps.21069

100

Ski CF, Taylor RS, McGuigan K, Long L, Lambert JD, Richards SH et al. Psychological interventions for depression and anxiety in patients with coronary heart disease, heart failure or atrial fibrillation. Cochrane Database of Systematic Reviews. 2024;2024(5):CD013508. DOI: 10.1002/14651858.CD013508.pub3

101

Ding N, Sang Y, Chen J, Ballew SH, Kalbaugh CA, Salameh MJ et al. Cigarette Smoking, Smoking Cessation, and Long-Term Risk of 3 Major Atherosclerotic Diseases. Journal of the American College of Cardiology. 2019;74(4):498–507. DOI: 10.1016/j.jacc.2019.05.049

102

Taylor GM, Lindson N, Farley A, Leinberger-Jabari A, Sawyer K, Te Water Naudé R et al. Smoking cessation for improving mental health. Cochrane Database of Systematic Reviews. 2021;2021(3):CD013522. DOI: 10.1002/14651858.CD013522.pub2

103

Wu AD, Lindson N, Hartmann-Boyce J, Wahedi A, Hajizadeh A, Theo doulou A et al. Smoking cessation for secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews. 2022;2022(8):CD014936. DOI: 10.1002/14651858.CD014936.pub2

104

Benowitz NL, Pipe A, West R, Hays JT, Tonstad S, McRae T et al. Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial. JAMA Internal Medicine. 2018;178(5):622–31. DOI: 10.1001/jamainternmed.2018.0397

105

Auer R, Schoeni A, Humair J-P, Jacot-Sadowski I, Berlin I, Stuber MJ et al. Electronic Nicotine-Delivery Systems for Smoking Cessation. New England Journal of Medicine. 2024;390(7):601–10. DOI: 10.1056/NEJMoa2308815

106

Lindson N, Butler AR, McRobbie H, Bullen C, Hajek P, Begh R et al. Electronic cigarettes for smoking cessation. Cochrane Database of Systematic Reviews. 2024;2024(1):CD010216. DOI: 10.1002/14651858.CD010216.pub8

107

Livingstone-Banks J, Fanshawe TR, Thomas KH, Theodoulou A, Hajizadeh A, Hartman L et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews. 2023;2024(5):CD006103. DOI: 10.1002/14651858.CD006103.pub9

108

Rigotti NA, Benowitz NL, Prochaska J, Leischow S, Nides M, Blumenstein B et al. Cytisinicline for Smoking Cessation: A Randomized Clinical Trial. JAMA. 2023;330(2):152–60. DOI: 10.1001/jama.2023.10042

109

Tuisku A, Rahkola M, Nieminen P, Toljamo T. Electronic Cigarettes vs Varenicline for Smoking Cessation in Adults: A Randomized Clinical Trial. JAMA Internal Medicine. 2024;184(8):915–21. DOI: 10.1001/jamainternmed.2024.1822

110

Krittanawong C, Isath A, Rosenson RS, Khawaja M, Wang Z, Fogg SE et al. Alcohol Consumption and Cardiovascular Health. The American Journal of Medicine. 2022;135(10):1213-1230.e3. DOI: 10.1016/j.amjmed.2022.04.021

111

Biddinger KJ, Emdin CA, Haas ME, Wang M, Hindy G, Ellinor PT et al. Association of Habitual Alcohol Intake With Risk of Cardiovascular Disease. JAMA Network Open. 2022;5(3):e223849. DOI: 10.1001/jamanetworkopen.2022.3849

112

Millwood IY, Walters RG, Mei XW, Guo Y, Yang L, Bian Z et al. Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 men and women in China. The Lancet. 2019;393(10183):1831–42. DOI: 10.1016/S01406736(18)31772-0

113

Holmes MV, Dale CE, Zuccolo L, Silverwood RJ, Guo Y, Ye Z et al. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ. 2014;349:g4164. DOI: 10.1136/bmj.g4164

114

Jayakody K, Gunadasa S, Hosker C. Exercise for anxiety disorders: systematic review. British Journal of Sports Medicine. 2014;48(3):187–96. DOI: 10.1136/bjsports-2012-091287

115

Hallgren M, Nguyen T-T-D, Herring MP, McDowell CP, Gordon BR, Stubbs B et al. Associations of physical activity with anxiety symptoms and disorders: Findings from the Swedish National March Cohort. General Hospital Psychiatry. 2019;58:45–50. DOI: 10.1016/j.genhosppsych.2019.03.001

116

Yu Q, Wong K-K, Lei O-K, Nie J, Shi Q, Zou L et al. Comparative Effectiveness of Multiple Exercise Interventions in the Treatment of Mental Health Disorders: A Systematic Review and Network Meta-Analysis. Sports Medicine - Open. 2022;8(1):135. DOI: 10.1186/s40798-022-00529-5

117

Cooney GM, Dwan K, Greig CA, Lawlor DA, Rimer J, Waugh FR et al. Exercise for depression. Cochrane Database of Systematic Reviews. 2013;2013(9):CD004366. DOI: 10.1002/14651858.CD004366.pub6

118

Gordon BR, McDowell CP, Hallgren M, Meyer JD, Lyons M, Herring MP. Association of Efficacy of Resistance Exercise Training With Depressive Symptoms: Meta-analysis and Meta-regression Analysis of Randomized Clinical Trials. JAMA Psychiatry. 2018;75(6):566–76. DOI: 10.1001/jamapsychiatry.2018.0572

119

Carmin CN, Ownby RL, Fontanella C, Steelesmith D, Binkley PF. Impact of Mental Health Treatment on Outcomes in Patients With Heart Failure and Ischemic Heart Disease. Journal of the American Heart Association. 2024;13(7):e031117. DOI: 10.1161/JAHA.123.031117

120

Van Dis EAM, Van Veen SC, Hagenaars MA, Batelaan NM, Bockting CLH, Van Den Heuvel RM et al. Long-term Outcomes of Cognitive Behavioral Therapy for Anxiety-Related Disorders: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2020;77(3):265–73. DOI: 10.1001/jamapsychiatry.2019.3986

121

Papola D, Ostuzzi G, Tedeschi F, Gastaldon C, Purgato M, Del Giovane C et al. Comparative efficacy and acceptability of psychotherapies for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials. The British Journal of Psychiatry. 2022;221(3):507–19. DOI: 10.1192/bjp.2021.148

122

Papola D, Miguel C, Mazzaglia M, Franco P, Tedeschi F, Romero SA et al. Psychotherapies for Generalized Anxiety Disorder in Adults: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. JAMA Psychiatry. 2024;81(3):250–9. DOI: 10.1001/jamapsychiatry.2023.3971

123

Plessen CY, Karyotaki E, Miguel C, Ciharova M, Cuijpers P. Exploring the efficacy of psychotherapies for depression: a multiverse metaanalysis. BMJ Mental Health. 2023;26(1):e300626. DOI: 10.1136/bmjment-2022-300626

124

Kolovos S, Kleiboer A, Cuijpers P. Effect of psychotherapy for depression on quality of life: meta-analysis. British Journal of Psychiatry. 2016;209(6):460–8. DOI: 10.1192/bjp.bp.115.175059

125

Hofmann SG, Wu JQ, Boettcher H. Effect of cognitive-behavioral therapy for anxiety disorders on quality of life: A meta-analysis. Journal of Consulting and Clinical Psychology. 2014;82(3):375–91. DOI: 10.1037/a0035491

126

Karyotaki E, Efthimiou O, Miguel C, Maas Genannt Bermpohl F, Furukawa TA, Cuijpers P et al. Internet-Based Cognitive Behavioral Therapy for Depression: A Systematic Review and Individual Patient Data Network Meta-analysis. JAMA Psychiatry. 2021;78(4):361–71. DOI: 10.1001/jamapsychiatry.2020.4364

127

Hedman‐Lagerlöf E, Carlbring P, Svärdman F, Riper H, Cuijpers P, Andersson G. Therapist‐supported Internet‐based cognitive behaviour therapy yields similar effects as face‐to‐face therapy for psychiatric and somatic disorders: an updated systematic review and meta‐analysis. World Psychiatry. 2023;22(2):305–14. DOI: 10.1002/wps.21088

128

Ricci C, Wood A, Muller D, Gunter MJ, Agudo A, Boeing H et al. Alcohol intake in relation to non-fatal and fatal coronary heart disease and stroke: EPIC-CVD case-cohort study. BMJ. 2018;361:k934. DOI: 10.1136/bmj.k934

129

Pearce M, Garcia L, Abbas A, Strain T, Schuch FB, Golubic R et al. Association Between Physical Activity and Risk of Depression: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2022;79(6):550–9. DOI: 10.1001/jamapsychiatry.2022.0609

130

Jones ME, Campbell G, Patel D, Brunner E, Shatapathy CC, MurrayThomas T et al. Risk of Mortality (including Sudden Cardiac Death) and Major Cardiovascular Events in Users of Olanzapine and Other Antipsychotics: A Study with the General Practice Research Database. Cardiovascular Psychiatry and Neurology. 2013;2013:1–13. DOI: 10.1155/2013/647476

131

Wu C, Tsai Y, Tsai H. Antipsychotic Drugs and the Risk of Ventricular Arrhythmia and/or Sudden Cardiac Death: A Nation‐wide Case‐Crossover Study. Journal of the American Heart Association. 2015;4(2):e001568. DOI: 10.1161/JAHA.114.001568

132

Weeke P, Jensen A, Folke F, Gislason GH, Olesen JB, Fosbøl EL et al. Antipsychotics and Associated Risk of Out-of-Hospital Cardiac Arrest. Clinical Pharmacology & Therapeutics. 2014;96(4):490–7. DOI: 10.1038/clpt.2014.139

133

Белялов Ф.И. Лечение болезней в условиях коморбидности. 12-е изд. - М.: ГЭОТАР-Медиа; 2022. - 546с. ISBN 978-5-9704-6360-4

Belialov F.I. Treatment of diseases in comorbidity. 12th ed. - M.: GEOTAR-Media; 2022. - 546p. ISBN 978-5-9704-6360-4

134

Piña IL, Di Palo KE, Ventura HO. Psychopharmacology and Cardiovascular Disease. Journal of the American College of Cardiology. 2018;71(20):2346–59. DOI: 10.1016/j.jacc.2018.03.458

135

Мосолов С.Н., Малин Д.И., Рывкин П.В., Сычев Д.А. Лекарственные взаимодействия препаратов, применяемых в психиатрической практике. Современная терапия психических расстройств. 2019:S1:2-33. DOI: 10.21265/PSYPH.2019.50.40828

Mosolov S.N., Malin D.I., Ryvkin P.V., Sychev D.A. Psychotropic Drugs Interactions. Modern therapy of mental disorders. 2019;S1:2–33. DOI: 10.21265/PSYPH.2019.50.40828

136

Fanoe S, Kristensen D, Fink-Jensen A, Jensen HK, Toft E, Nielsen J et al. Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management. European Heart Journal. 2014;35(20):1306–15. DOI: 10.1093/eurheartj/ehu100

137

Beach SR, Celano CM, Sugrue AM, Adams C, Ackerman MJ, Noseworthy PA et al. QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update. Psychosomatics. 2018;59(2):105–22. DOI: 10.1016/j.psym.2017.10.009

138

Castro VM, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ. 2013;346:f288. DOI: 10.1136/bmj.f288

139

Малин Д.И., Булатова Д.Р., Шустова Л.Ю., Гордеева Р.П. Распространенность и факторы риска синдрома удлинения интервала QT у пациентов городской психиатрической больницы. Современная терапия психических расстройств. 2023;3:50-6. DOI: 10.21265/PSYPH.2023.60.92.006

Malin D.I., Bulatova D.R., Shustova L.Yu., Gordeeva R.P. Prevalence and risk factors of QT prolongation syndrome in patients of the city psychiatric hospital. Modern therapy of mental disorders. 2023;3:50–6. DOI: 10.21265/PSYPH.2023.60.92.006

140

Kasper S, Gastpar M, Müller WE, Volz H-P, Möller H-J, Schläfke S et al. Lavender oil preparation Silexan is effective in generalized anxiety disorder – a randomized, double-blind comparison to placebo and paroxetine. The International Journal of Neuropsychopharmacology. 2014;17(06):859–69. DOI: 10.1017/S1461145714000017

141

Donelli D, Antonelli M, Bellinazzi C, Gensini GF, Firenzuoli F. Effects of lavender on anxiety: A systematic review and meta-analysis. Phytomedicine. 2019;65:153099. DOI: 10.1016/j.phymed.2019.153099

142

Zhao X, Zhang H, Wu Y, Yu C. The efficacy and safety of St. John’s wort extract in depression therapy compared to SSRIs in adults: A meta-analysis of randomized clinical trials. Advances in Clinical and Experimental Medicine. 2022;32(2):151–61. DOI: 10.17219/acem/152942

143

Cui YH, Zheng Y. A meta-analysis on the efficacy and safety of St John’s wort extract in depression therapy in comparison with selective serotonin reuptake inhibitors in adults. Neuro-psychiatric Disease and Treatment. 2016;12:1715–23. DOI: 10.2147/NDT.S106752

144

Sartorius N, Baghai TC, Baldwin DS, Barrett B, Brand U, Fleischhacker W et al. Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. The International Journal of Neuropsychopharmacology. 2007;10(Suppl 1):S1-207. DOI: 10.1017/S1461145707008255

145

Baldwin DS, Stein DJ, Dolberg OT, Bandelow B. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Human Psychopharmacology: Clinical and Experimental. 2009;24(4):269–75. DOI: 10.1002/hup.1019

146

De Vries YA, Roest AM, Bos EH, Burgerhof JGM, Van Loo HM, De Jonge P. Predicting antidepressant response by monitoring early improvement of individual symptoms of depression: individual patient data meta-analysis. British Journal of Psychiatry. 2019;214(1):4–10. DOI: 10.1192/bjp.2018.122

147

Cleare A, Pariante C, Young A, Anderson I, Christmas D, Cowen P et al. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology. 2015;29(5):459–525. DOI: 10.1177/0269881115581093

148

Nochaiwong S, Ruengorn C, Awiphan R, Chai-Adisaksopha C, Tantraworasin A, Phosuya C et al. Use of serotonin reuptake inhibitor antidepressants and the risk of bleeding complications in patients on anticoagulant or antiplatelet agents: a systematic review and meta-analysis. Annals of Medicine. 2022;54(1):80–97. DOI: 10.1080/07853890.2021.2017474

149

Laporte S, Chapelle C, Caillet P, Beyens M-N, Bellet F, Delavenne X et al. Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: A meta-analysis of observational studies. Pharmacological Research. 2017;118:19–32. DOI: 10.1016/j.phrs.2016.08.017

150

Montastruc J-L, Bura-Rivière A. Association of antidepressants plus antithrombotics and bleeding risk: a pharmacovigilance study. European Journal of Clinical Pharmacology. 2024;80(2):283–5. DOI: 10.1007/s00228-023-03590-5

151

Axelsson MAB, Tukukino C, Parodi López N, Wallerstedt SM. Bleeding in patients on concurrent treatment with a selective serotonin reuptake inhibitor (SSRI) and low‐dose acetylsalicylic acid (ASA) compared with SSRI or low‐dose ASA alone – A systematic review and meta‐analysis. British Journal of Clinical Pharmacology. 2024;90(4):916–32. DOI: 10.1111/bcp.16000

152

Perahia DG, Bangs ME, Zhang Q, Cheng Y, Ahl J, Frakes E et al. The risk of bleeding with duloxetine treatment in patients who use nonsteroidal anti-inflammatory drugs (NSAIDs): analysis of placebo-controlled trials and post-marketing adverse event reports. Drug, Healthcare and Patient Safety. 2013;5:211–9. DOI: 10.2147/DHPS. S45445

153

Rahman AA, Platt RW, Beradid S, Boivin J-F, Rej S, Renoux C. Concomitant Use of Selective Serotonin Reuptake Inhibitors With Oral Anticoagulants and Risk of Major Bleeding. JAMA Network Open. 2024;7(3):e243208. DOI: 10.1001/jamanetworkopen.2024.3208

154

Gandhi S, Shariff SZ, Al-Jaishi A, Reiss JP, Mamdani MM, Hackam DG et al. Second-Generation Antidepressants and Hyponatremia Risk: A Population-Based Cohort Study of Older Adults. American Journal of Kidney Diseases. 2017;69(1):87–96. DOI: 10.1053/j.ajkd.2016.08.020

155

Viramontes TS, Truong H, Linnebur SA. Antidepressant-Induced Hyponatremia in Older Adults. The Consultant Pharmacist. 2016;31(3):139–50. DOI: 10.4140/TCP.n.2016.139

156

Gheysens T, Van Den Eede F, De Picker L. The risk of antidepressantinduced hyponatremia: A meta-analysis of antidepressant classes and compounds. European Psychiatry. 2024;67(1):e20. DOI: 10.1192/j.eurpsy.2024.11

157

Ojero-Senard A, Benevent J, Bondon-Guitton E, Durrieu G, Chebane L, Araujo M et al. A comparative study of QT prolongation with serotonin reuptake inhibitors. Psychopharmacology. 2017;234(20):3075–81. DOI: 10.1007/s00213-017-4685-7

158

Funk KA, Bostwick JR. A Comparison of the Risk of QT Prolongation Among SSRIs. Annals of Pharmacotherapy. 2013;47(10):1330–41. DOI: 10.1177/1060028013501994

159

Beach SR, Kostis WJ, Celano CM, Januzzi JL, Ruskin JN, Noseworthy PA et al. Meta-Analysis of Selective Serotonin Reuptake Inhibitor–Associated QTc Prolongation. The Journal of Clinical Psychiatry. 2014;75(5):e441–9. DOI: 10.4088/JCP.13r08672

160

Van Leeuwen E, Van Driel ML, Horowitz MA, Kendrick T, Donald M, De Sutter AI et al. Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults. Cochrane Database of Systematic Reviews. 2021;2021(4):CD013495. DOI: 10.1002/14651858.CD013495.pub2

161

Cohen D, Recalt A. Discontinuing Psychotropic Drugs from Participants in Randomized Controlled Trials: A Systematic Review. Psychotherapy and Psychosomatics. 2019;88(2):96–104. DOI: 10.1159/000496733

162

Хасанова А.К., Мосолов С.Н. Синдромом отмены приема антидепрессантов (алгоритм профилактики и коррекции). Современная терапия психических расстройств. 2023;2:37–47. DOI: 10.21265/PSYPH.2023.15.79.005

Khasanova A.K., Mosolov S.N. Withdrawal syndrome of antidepressants (algorithm of prevention and correction). Modern therapy of mental disorders. 2023;2:37–47. DOI: 10.21265/PSYPH.2023.15.79.005

163

NICE. Generalised anxiety disorder and panic disorder in adults: management. - London: NICE; 2019. - 43p. ISBN 978-1-4731-2854-5

164

De Las Cuevas C, Sanz E, De La Fuente J. Benzodiazepines: more ‘behavioural’ addiction than dependence. Psychopharmacology. 2003;167(3):297–303. DOI: 10.1007/s00213-002-1376-8

165

Donnelly K, Bracchi R, Hewitt J, Routledge PA, Carter B. Benzodiazepines, Z-drugs and the risk of hip fracture: A systematic review and meta-analysis. PLOS ONE. 2017;12(4):e0174730. DOI: 10.1371/journal.pone.0174730

166

Poly TN, Islam MdM, Yang H-C, Li Y-C (Jack). Association between benzodiazepines use and risk of hip fracture in the elderly people: A meta-analysis of observational studies. Joint Bone Spine. 2020;87(3):241–9. DOI: 10.1016/j.jbspin.2019.11.003

167

Burschinski A, Schneider‐Thoma J, Chiocchia V, Schestag K, Wang D, Siafis S et al. Metabolic side effects in persons with schizophrenia during mid‐ to long‐term treatment with antipsychotics: a network meta‐analysis of randomized controlled trials. World Psychiatry. 2023;22(1):116–28. DOI: 10.1002/wps.21036

168

Erickson SC, Le L, Zakharyan A, Stockl KM, Harada ASM, Borson S et al. New‐Onset Treatment‐Dependent Diabetes Mellitus and Hyperlipidemia Associated with Atypical Antipsychotic Use in Older Adults without Schizophrenia or Bipolar Disorder. Journal of the American Geriatrics Society. 2012;60(3):474–9. DOI: 10.1111/j.1532-5415.2011.03842.x

169

Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. The Lancet. 2019;394(10202):939–51. DOI: 10.1016/S0140-6736(19)31135-3

170

Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. The Lancet Psychiatry. 2020;7(1):64–77. DOI: 10.1016/S2215-0366(19)30416-X

171

Wu H, Siafis S, Hamza T, Schneider-Thoma J, Davis JM, Salanti G et al. Antipsychotic-Induced Weight Gain: Dose-Response MetaAnalysis of Randomized Controlled Trials. Schizophrenia Bulletin. 2022;48(3):643–54. DOI: 10.1093/schbul/sbac001

172

Whicher CA, Price HC, Holt RIG. Mechanisms in endocrinology: Antipsychotic medication and type 2 diabetes and impaired glucose regulation. European Journal of Endocrinology. 2018;178(6):R245–58. DOI: 10.1530/EJE-18-0022

173

Ono S, Someya T. Lipid Metabolism Disturbances During Antipsychotic Treatment for Schizophrenia. P.987-1004. DOI: 10.1007/9783-030-62059-2_402. In: NeuroPsychopharmacotherapy. - Cham: Springer International Publishing; 2022. ISBN: 978-3-030-62058-5

174

Correll CU, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastaso P et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large‐scale meta‐analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16(2):163–80. DOI: 10.1002/wps.20420

175

Zivkovic S, Koh CH, Kaza N, Jackson CA. Antipsychotic drug use and risk of stroke and myocardial infarction: a systematic review and meta-analysis. BMC Psychiatry. 2019;19(1):189. DOI: 10.1186/s12888-019-2177-5

176

Ray WA, Stein CM, Murray KT, Fuchs DC, Patrick SW, Daugherty J et al. Association of Antipsychotic Treatment With Risk of Unexpected Death Among Children and Youths. JA-MA Psychiatry. 2019;76(2):162–71. DOI: 10.1001/jamapsychiatry.2018.3421

177

Suvisaari J, Partti K, Perälä J, Viertiö S, Saarni SE, Lönnqvist J et al. Mortality and Its Determinants in People With Psychotic Disorder. Psychosomatic Medicine. 2013;75(1):60–7. DOI: 10.1097/PSY.0b013e31827ad512

178

Salvo F, Pariente A, Shakir S, Robinson P, Arnaud M, Thomas S et al. Sudden cardiac and sudden unexpected death related to antipsychotics: A meta‐analysis of observational studies. Clinical Pharmacology & Therapeutics. 2016;99(3):306–14. DOI: 10.1002/cpt.250

179

Huang K-L, Fang C-J, Hsu C-C, Wu S-I, Juang JJ, Stewart R. Myocardial infarction risk and antipsychotics use revisited: a meta-analysis of 10 observational studies. Journal of Psychopharmacology. 2017;31(12):1544–55. DOI: 10.1177/0269881117714047

180

Yu Z, Jiang H, Shao L, Zhou Y, Shi H, Ruan B. Use of antipsychotics and risk of myocardial infarction: a systematic review and meta‐analysis. British Journal of Clinical Pharmacology. 2016;82(3):624–32. DOI: 10.1111/bcp.12985

181

Almuwaqqat Z, Jokhadar M, Norby FL, Lutsey PL, O’Neal WT, Seyerle A et al. Association of Antidepressant Medication Type With the Incidence of Cardiovascular Disease in the ARIC Study. Journal of the American Heart Association. 2019;8(11):e012503. DOI: 10.1161/JAHA.119.012503

182

Coupland C, Hill T, Morriss R, Moore M, Arthur A, HippisleyCox J. Antidepressant use and risk of cardiovascular outcomes in people aged 20 to 64: cohort study using primary care database. BMJ. 2016;352:i1350. DOI: 10.1136/bmj.i1350

183

Mease PJ, Zimetbaum PJ, Duh MS, Vekeman F, Guérin A, Boerstoel-Streefland M et al. Epidemiologic Evaluation of Cardiovascular Risk in Patients Receiving Milnacipran, Venlafaxine, or Amitriptyline: Evidence from French Health Data. Annals of Pharmacotherapy. 2011;45(2):179–88. DOI: 10.1345/aph.1P391

184

Maslej MM, Bolker BM, Russell MJ, Eaton K, Durisko Z, Hollon SD et al. The Mortality and Myocardial Effects of Antidepressants Are Moderated by Preexisting Cardiovascular Disease: A Meta-Analysis. Psychotherapy and Psychosomatics. 2017;86(5):268–82. DOI: 10.1159/000477940

185

Kim JH, Song Y-K, Jang HY, Shin J-Y, Lee H-Y, Ahn YM et al. Major Adverse Cardiovascular Events in Antidepressant Users Within Patients With Ischemic Heart Diseases: A Nationwide Cohort Study. Journal of Clinical Psychopharmacology. 2020;40(5):475–81. DOI: 10.1097/JCP.0000000000001252

186

Cheng Y-L, Hu H-Y, Lin X-H, Luo J-C, Peng Y-L, Hou M-C et al. Use of SSRI, But Not SNRI, Increased Upper and Lower Gastrointestinal Bleeding: A Nationwide Population-Based Cohort Study in Taiwan. Medicine. 2015;94(46):e2022. DOI: 10.1097/MD.0000000000002022

187

De Abajo FJ, García-Rodríguez LA. Risk of Upper Gastrointestinal Tract Bleeding Associated With Selective Serotonin Reuptake Inhibitors and Venlafaxine Therapy: Interaction With Nonsteroidal Anti-inflammatory Drugs and Effect of Acid-Suppressing Agents. Archives of General Psychiatry. 2008;65(7):795–803. DOI: 10.1001/archpsyc.65.7.795

188

Andersson NW, Wohlfahrt J, Feenstra B, Hviid A, Melbye M, Lund M. Cumulative Incidence of Thiazide-Induced Hyponatremia: A Population-Based Cohort Study. Annals of Internal Medicine. 2024;177(1):1–11. DOI: 10.7326/M23-1989

189

Lane NE, Bai L, Seitz DP, Juurlink DN, Paterson JM, Guan J et al. Hyponatremia‐associated hospital visits are not reduced by early electrolyte testing in older adults starting antidepressants. Journal of the American Geriatrics Society. 2024;72(6):1770–80. DOI: 10.1111/jgs.18930

190

Jang HY, Kim JH, Song Y-K, Shin J-Y, Lee H-Y, Ahn YM et al. Antidepressant Use and the Risk of Major Adverse Cardiovascular Events in Patients Without Known Cardiovascular Disease: A Retrospective Cohort Study. Frontiers in Pharmacology. 2020;11:594474. DOI: 10.3389/fphar.2020.594474

191

Хасанова А.К. Применение антидепрессантов и риск падения у пациентов старшего возраста. Современная терапия психических расстройств. 2022;4:25–33. DOI: 10.21265/PSYPH.2022.74.75.004

Khasanova A.K. The use of antidepressants and the risk of falling in older patients. Modern therapy of mental disorders. 2022;4:25–33. DOI: 10.21265/PSYPH.2022.74.75.004

192

Henssler J, Schmidt Y, Schmidt U, Schwarzer G, Bschor T, Baethge C. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. The Lancet Psychiatry. 2024;11(7):526–35. DOI: 10.1016/S2215-0366(24)00133-0

193

AlDawsari A, Bushell TJ, Abutheraa N, Sakata S, Al Hussain S, Kurdi A. Use of sedative‐hypnotic medications and risk of dementia: A systematic review and meta‐analysis. British Journal of Clinical Pharmacology. 2022;88(4):1567–89. DOI: 10.1111/bcp.15113

194

Osler M, Jørgensen MB. Associations of Benzodiazepines, Z-Drugs, and Other Anxiolytics With Subsequent Dementia in Patients With Affective Disorders: A Nationwide Cohort and Nested Case-Control Study. American Journal of Psychiatry. 2020;177(6):497–505. DOI: 10.1176/appi.ajp.2019.19030315

195

Hoskins MD, Bridges J, Sinnerton R, Nakamura A, Underwood JFG, Slater A et al. Pharmacological therapy for post-traumatic stress disorder: a systematic review and meta-analysis of monotherapy, augmentation and head-to-head approaches. European Journal of Psychotraumatology. 2021;12(1):1802920. DOI: 10.1080/20008198.2020.1802920

196

Komossa K, Depping AM, Meyer M, Kissling W, Leucht S. Secondgeneration antipsychotics for obsessive compulsive disorder. Cochrane Database of Systematic Reviews. 2010;12:CD008121. DOI: 10.1002/14651858.CD008141.pub2

197

Depping AM, Komossa K, Kissling W, Leucht S. Second-generation antipsychotics for anxiety disorders. Cochrane Database of Systematic Reviews. 2010;12:CD008120. DOI: 10.1002/14651858.CD008120.pub2

198

Министерство здравоохранения Российской Федерации. Российское общество психиатров. Шизофрения. 2024. 133 с. Доступно на: https://cr.minzdrav.gov.ru/preview-cr/451_3

Ministry of Health of the Russian Federation. Russian Society of Psychiatrists. Schizophrenia. 2024. 133 p. Av. at: https://cr.minzdrav.gov.ru/preview-cr/451_3

199

Министерство здравоохранения Российской Федерации. Российское общество психиатров. Биполярное аффективное расстройство. 2021. 161 с. Доступно на: https://cr.minzdrav.gov.ru/preview-cr/675_1

Ministry of Health of the Russian Federation. Russian Society of Psychiatrists. Bipolar disorder. 2021. 161 p. Av. at: https://cr.minzdrav.gov.ru/preview-cr/675_1

200

Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH et al. Risk of Death in Elderly Users of Conventional vs. Atypical Antipsychotic Medications. New England Journal of Medicine. 2005;353(22):2335–41. DOI: 10.1056/NEJMoa052827

201

Hasnain M, Vieweg WVR. QTc Interval Prolongation and Torsade de Pointes Associated with Second-Generation Antipsychotics and Antidepressants: A Comprehensive Review. CNS Drugs. 2014;28(10):887–920. DOI: 10.1007/s40263-014-0196-9

202

Mok PLH, Carr MJ, Guthrie B, Morales DR, Sheikh A, Elliott RA et al. Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study. BMJ. 2024;385:e076268. DOI: 10.1136/bmj-2023-076268

203

Yunusa I, Alsumali A, Garba AE, Regestein QR, Eguale T. Assessment of Reported Comparative Effectiveness and Safety of Atypical Antipsychotics in the Treatment of Behavioral and Psychological Symptoms of Dementia: A Network Meta-analysis. JAMA Network Open. 2019;2(3):e190828. DOI: 10.1001/jamanetworkopen.2019.0828

204

Yunusa I, Rashid N, Demos GN, Mahadik BS, Abler VC, Rajagopalan K. Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis. Advances in Therapy. 2022;39(5):1993–2008. DOI: 10.1007/s12325-022-02075-8

205

Медведев В.Э. Алимемазин в психиатрии и психосоматике. Психиатрия и психофармакотерапия. 2018;20(3-4):26-33

Medvedev V.E. Alimemazine in psychiatry and psychosomatic. Psychiatry and Psychopharmacotherapy. 2018;20(3–4):26–33.

206

Tan H, Yan X, Chen Y, Huang G, Luo L, Li W et al. A real-world pharmacovigilance study of drug-induced QT interval prolongation: analysis of spontaneous reports submitted to FAERS. Frontiers in Cardiovascular Medicine. 2024;11:1363382. DOI: 10.3389/fcvm.2024.1363382

207

Olariu E, Forero CG, Castro-Rodriguez JI, Rodrigo-Calvo MT, Álvarez P, Martín-López LM et al. Detection of anxiety disorders in primary care: a meta-analysis of assisted and unassisted diagnoses. Depression and Anxiety. 2015;32(7):471–84. DOI: 10.1002/da.22360

208

Незнанов Н.Г., Мартынихин И.А., Мосолов С.Н. Диагностика и терапия тревожных расстройств в Российской Федерации: результаты опроса врачей психиатров. Современная терапия психических расстройств. 2017;2:2-13. DOI: 10.21265/PSYPH.2017.41.6437

Neznanov N.G., Martynikhin I.A., Mosolov S.N. Diagnosis and therapy of anxiety disorders in the Russian Federation: results of a survey of psychiatrists. Modern therapy of mental disorders. 2017;2:2–13. DOI: 10.21265/PSYPH.2017.41.6437

209

McGrath JJ, Al-Hamzawi A, Alonso J, Altwaijri Y, Andrade LH, Bromet EJ et al. Age of onset and cumulative risk of mental disorders: a cross-national analysis of population surveys from 29 countries. The Lancet Psychiatry. 2023;10(9):668–81. DOI: 10.1016/S2215-0366(23)00193-1

210

Bandelow B, Werner AM, Kopp I, Rudolf S, Wiltink J, Beutel ME. The German Guidelines for the treatment of anxiety disorders: first revision. European Archives of Psychiatry and Clinical Neuroscience. 2022;272(4):571–82. DOI: 10.1007/s00406-021-01324-1

211

Bandelow B, Reitt M, Röver C, Michaelis S, Görlich Y, Wedekind D. Efficacy of treatments for anxiety disorders: a meta-analysis. International Clinical Psychopharmacology. 2015;30(4):183–92. DOI: 10.1097/YIC.0000000000000078

212

Furukawa TA, Watanabe N, Churchill R. Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia. Cochrane Database of Systematic Reviews. 2007;1:CD004364. DOI: 10.1002/14651858.CD004364.pub2

213

Carpenter JK, Andrews LA, Witcraft SM, Powers MB, Smits JAJ, Hofmann SG. Cognitive behavioral therapy for anxiety and related disorders: A meta‐analysis of randomized placebo‐controlled trials. Depression and Anxiety. 2018;35(6):502–14. DOI: 10.1002/da.22728

214

Bolgeo T, Di Matteo R, Simonelli N, Dal Molin A, Lusignani M, Bassola B et al. Psychometric properties and measurement invariance of the 7-item General Anxiety Disorder scale (GAD-7) in an Italian coronary heart disease population. Journal of Affective Disorders. 2023;334:213–9. DOI: 10.1016/j.jad.2023.04.140

215

Guaiana G, Meader N, Barbui C, Davies SJ, Furukawa TA, Imai H et al. Pharmacological treatments in panic disorder in adults: a network meta-analysis. Cochrane Database of Systematic Reviews. 2023;11:CD012729. DOI: 10.1002/14651858.CD012729.pub3

216

Slee A, Nazareth I, Bondaronek P, Liu Y, Cheng Z, Freemantle N. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. The Lancet. 2019;393(10173):768–77. DOI: 10.1016/S0140-6736(18)31793-8

217

Generoso MB, Trevizol AP, Kasper S, Cho HJ, Cordeiro Q, Shiozawa P. Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis. International Clinical Psychopharmacology. 2017;32(1):49–55. DOI: 10.1097/YIC.0000000000000147

218

Carl E, Witcraft SM, Kauffman BY, Gillespie EM, Becker ES, Cuijpers P et al. Psychological and pharmacological treatments for generalized anxiety disorder (GAD): a meta-analysis of randomized controlled trials. Cognitive Behaviour Therapy. 2020;49(1):1–21. DOI: 10.1080/16506073.2018.1560358

219

Stubbs B, Vancampfort D, Rosenbaum S, Firth J, Cosco T, Veronese N et al. An examination of the anxiolytic effects of exercise for people with anxiety and stress-related disorders: A meta-analysis. Psychiatry Research. 2017;249:102–8. DOI: 10.1016/j.psychres.2016.12.020

220

Ramos-Sanchez CP, Schuch FB, Seedat S, Louw QA, Stubbs B, Rosenbaum S et al. The anxiolytic effects of exercise for people with anxiety and related disorders: An update of the available meta-analytic evidence. Psychiatry Research. 2021;302:114046. DOI: 10.1016/j.psychres.2021.114046

221

Rebar AL, Stanton R, Geard D, Short C, Duncan MJ, Vandelanotte C. A meta-meta-analysis of the effect of physical activity on depression and anxiety in non-clinical adult populations. Health Psychology Review. 2015;9(3):366–78. DOI: 10.1080/17437199.2015.1022901

222

Donovan MR, Glue P, Kolluri S, Emir B. Comparative efficacy of antidepressants in preventing relapse in anxiety disorders – A metaanalysis. Journal of Affective Disorders. 2010;123(1–3):9–16. DOI: 10.1016/j.jad.2009.06.021

223

Batelaan NM, Bosman RC, Muntingh A, Scholten WD, Huijbregts KM, Van Balkom AJLM. Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and posttraumatic stress disorder: systematic review and meta-analysis of relapse prevention trials. BMJ. 2017;358:j3927. DOI: 10.1136/bmj.j3927

224

Perna G, Alciati A, Riva A, Micieli W, Caldirola D. Long-Term Pharmacological Treatments of Anxiety Disorders: An Updated Systematic Review. Current Psychiatry Reports. 2016;18(3):23. DOI: 10.1007/s11920-016-0668-3

225

Nelson HD, Cantor A, Pappas M, Weeks C. Screening for Anxiety in Adolescent and Adult Women: A Systematic Review for the Women’s Preventive Services Initiative. Annals of Internal Medicine. 2020;173(1):29–41. DOI: 10.7326/M20-0579

226

Guaiana G, Barbui C, Cipriani A. Hydroxyzine for generalised anxiety disorder. Cochrane Database of Systematic Reviews. 2010;12:CD006815. DOI: 10.1002/14651858.CD006815.pub2

227

Breilmann J, Girlanda F, Guaiana G, Barbui C, Cipriani A, Castellazzi M et al. Benzodiazepines versus placebo for panic disorder in adults. Cochrane Database of Systematic Reviews. 2019;3:CD010677. DOI: 10.1002/14651858.CD010677.pub2

228

Guerlais M, Grall-Bronnec M, Feuillet F, Gérardin M, Jolliet P, Victorri-Vigneau C. Dependence on Prescription Benzodiazepines and Zdrugs Among Young to Middle-aged Patients in France. Substance Use & Misuse. 2015;50(3):320–7. DOI: 10.3109/10826084.2014.980952

229

Martin JLR, Sainz-Pardo M, Furukawa TA, Martin-Sanchez E, Seoane T, Galan C. Review: Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. Journal of Psychopharmacology. 2007;21(7):774–82. DOI: 10.1177/0269881107077355

230

Shinfuku M, Kishimoto T, Uchida H, Suzuki T, Mimura M, Kikuchi T. Effectiveness and safety of long-term benzodiazepine use in anxiety disorders: a systematic review and meta-analysis. International Clinical Psychopharmacology. 2019;34(5):211–21. DOI: 10.1097/YIC.0000000000000276

231

Teppo K, Jaakkola J, Airaksinen KEJ, Biancari F, Halminen O, Putaala J et al. Mental Health Conditions and Nonpersistence of Direct Oral Anticoagulant Use in Patients With Incident Atrial Fibrillation: A Nationwide Cohort Study. Journal of the American Heart Association. 2022;11(6):e024119. DOI: 10.1161/JAHA.121.024119

232

Dempe C, Jünger J, Hoppe S, Katzenberger M-L, Möltner A, Ladwig K-H et al. Association of anxious and depressive symptoms with medication nonadherence in patients with stable coronary artery disease. Journal of Psychosomatic Research. 2013;74(2):122–7. DOI: 10.1016/j.jpsychores.2012.12.003

233

Фомичева А.В., Трошина Д.В., Симонов А.Н., Копылов Ф.Ю., Андреев Д.А., Волель Б.А. Влияние тревожных расстройств на приверженность антикоагулянтной терапии у пациентов с фибрилляцией предсердий. Терапевтический архив. 2022;94(9):1085-93. DOI: 10.26442/0040366 0.2022.09.201891

Fomicheva A.V., Troshina D.V., Simonov A.N., Kopylov F.Yu., Andreev D.A., Volel B.A. Impact of anxiety disorders on adherence to anticoagulant therapy in patients with atrial fibrillation. Therapeutic Archive. 2022;94(9):1085–93. DOI: 10.26442/0040366 0.2022.09.201891

234

Hu Z-C, Liu S-Y, Wu L-M, Shen L-S, Liu L-M, Li G-L et al. Factors influencing adherence to non-vitamin K antagonist oral anticoagulants in the early period after atrial fibrillation catheter ablation in China. Chinese Medical Journal. 2020;133(16):1989–91. DOI: 10.1097/CM9.0000000000001000

235

Kuhl EA, Fauerbach JA, Bush DE, Ziegelstein RC. Relation of Anxiety and Adherence to Risk-Reducing Recommendations Following Myocardial Infarction. The American Journal of Cardiology. 2009;103(12):1629–34. DOI: 10.1016/j.amjcard.2009.02.014

236

Baldwin D, Woods R, Lawson R, Taylor D. Efficacy of drug treatments for generalised anxiety disorder: systematic review and metaanalysis. BMJ. 2011;342:d1199. DOI: 10.1136/bmj.d1199

237

Kim H, Kim EJ. Effects of Relaxation Therapy on Anxiety Disorders: A Systematic Review and Meta-analysis. Archives of Psychiatric Nursing. 2018;32(2):278–84. DOI: 10.1016/j.apnu.2017.11.015

238

Daveney J, Panagioti M, Waheed W, Esmail A. Unrecognized bipolar disorder in patients with depression managed in primary care: A systematic review and meta-analysis. General Hospital Psychiatry. 2019;58:71–6. DOI: 10.1016/j.genhosppsych.2019.03.006

239

Cerimele JM, Chwastiak LA, Dodson S, Katon WJ. The Prevalence of Bipolar Disorder in Primary Care Patients With Depression or Other Psychiatric Complaints: A Systematic Review. Psychosomatics. 2013;54(6):515–24. DOI: 10.1016/j.psym.2013.05.009

240

Мосолов С.Н., Ушкалова А.В., Костюкова Е.Г., Шафаренко А.А., Алфимов П.В., Костюкова А.Б. Диагностика биполярного аффективного расстройства II типа среди пациентов с текущим диагнозом рекуррентного депрессивного расстройства. Современная терапия психических расстройств. 2014;2:2-12

Mosolov S.N., Ushkalova A.V., Kostyukova E.G., Shafarenko A.A., Alfimov P.V., Kostyukova A.B. Diagnosis of type II bipolar affective disorder among patients with a current diagnosis of recurrent depressive disorder. Modern therapy of mental disorders. 2014;2:2–12.

241

Yildiz A, Siafis S, Mavridis D, Vieta E, Leucht S. Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis. The Lancet Psychiatry. 2023;10(9):693–705. DOI: 10.1016/S2215-0366(23)00199-2

242

Gartlehner G, Dobrescu A, Chapman A, Toromanova A, Emprechtinger R, Persad E et al. Nonpharmacologic and Pharmacologic Treatments of Adult Patients With Major Depressive Disorder: A Systematic Review and Network Meta-analysis for a Clinical Guideline by the American College of Physicians. Annals of Internal Medicine. 2023;176(2):196–211. DOI: 10.7326/M22-1845

243

Cuijpers P, Oud M, Karyotaki E, Noma H, Quero S, Cipriani A et al. Psychologic Treatment of Depression Compared With Pharmacotherapy and Combined Treatment in Primary Care: A Network MetaAnalysis. The Annals of Family Medicine. 2021;19(3):262–70. DOI: 10.1370/afm.2676

244

Amick HR, Gartlehner G, Gaynes BN, Forneris C, Asher GN, Morgan LC et al. Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis. BMJ. 2015;351:h6019. DOI: 10.1136/bmj.h6019

245

Bockting CLH, Klein NS, Elgersma HJ, Van Rijsbergen GD, Slofstra C, Ormel J et al. Effectiveness of preventive cognitive therapy while tapering antidepressants versus maintenance antidepressant treatment versus their combination in prevention of depressive relapse or recurrence (DRD study): a three-group, multicentre, randomised controlled trial. The Lancet Psychiatry. 2018;5(5):401–10. DOI: 10.1016/S2215-0366(18)30100-7

246

Krijnen-de Bruin E, Scholten W, Muntingh A, Maarsingh O, Van Meijel B, Van Straten A et al. Psychological interventions to prevent relapse in anxiety and depression: A systematic review and metaanalysis. PLOS ONE. 2022;17(8):e0272200. DOI: 10.1371/journal.pone.0272200

247

Kuyken W, Hayes R, Barrett B, Byng R, Dalgleish T, Kessler D et al. Effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse or recurrence (PREVENT): a randomised controlled trial. The Lancet. 2015;386(9988):63–73. DOI: 10.1016/S0140-6736(14)62222-4

248

Breedvelt JJF, Brouwer ME, Harrer M, Semkovska M, Ebert DD, Cuijpers P et al. Psychological interventions as an alternative and add-on to antidepressant medication to prevent depressive relapse: systematic review and meta-analysis. The British Journal of Psychiatry. 2021;219(4):538–45. DOI: 10.1192/bjp.2020.198

249

Breedvelt JJF, Warren FC, Segal Z, Kuyken W, Bockting CL. Continuation of Antidepressants vs Sequential Psychological Interventions to Prevent Relapse in Depression: An Individual Participant Data Metaanalysis. JAMA Psychiatry. 2021;78(8):868–75. DOI: 10.1001/jamapsychiatry.2021.0823

250

Cuijpers P, Noma H, Karyotaki E, Vinkers CH, Cipriani A, Furukawa TA. A network meta‐analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry. 2020;19(1):92–107. DOI: 10.1002/wps.20701

251

Furukawa TA, Shinohara K, Sahker E, Karyotaki E, Miguel C, Ciharova M et al. Initial treatment choices to achieve sustained response in major depression: a systematic review and network meta‐analysis. World Psychiatry. 2021;20(3):387–96. DOI: 10.1002/wps.20906

252

Guidi J, Fava GA. Sequential Combination of Pharmacotherapy and Psychotherapy in Major Depressive Disorder: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2021;78(3):261–9. DOI: 10.1001/jamapsychiatry.2020.3650

253

Noetel M, Sanders T, Gallardo-Gómez D, Taylor P, Del Pozo Cruz B, Van Den Hoek D et al. Effect of exercise for depression: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2024;384:e075847. DOI: 10.1136/bmj-2023-075847

254

Tao Y, Lu J, Lv J, Zhang L. Effects of high-intensity interval training on depressive symptoms: A systematic review and meta-analysis. Journal of Psychosomatic Research. 2024;180:111652. DOI: 10.1016/j.jpsychores.2024.111652

255

Schuch F, Vancampfort D, Firth J, Rosenbaum S, Ward P, Reichert T et al. Physical activity and sedentary behavior in people with major depressive disorder: A systematic review and meta-analysis. Journal of Affective Disorders. 2017;210:139–50. DOI: 10.1016/j.jad.2016.10.050

256

Schuch FB, Vancampfort D, Richards J, Rosenbaum S, Ward PB, Stubbs B. Exercise as a treatment for depression: A meta-analysis adjusting for publication bias. Journal of Psychiatric Research. 2016;77:42–51. DOI: 10.1016/j.jpsychires.2016.02.023

257

Schuch FB, Vancampfort D, Rosenbaum S, Richards J, Ward PB, Stubbs B. Exercise improves physical and psychological quality of life in people with depression: A meta-analysis including the evaluation of control group response. Psychiatry Research. 2016;241:47–54. DOI: 10.1016/j.psychres.2016.04.054

258

Haddad M, Walters P, Phillips R, Tsakok J, Williams P, Mann A et al. Detecting Depression in Patients with Coronary Heart Disease: a Diagnostic Evaluation of the PHQ-9 and HADS-D in Primary Care, Findings From the UPBEAT-UK Study. PLoS ONE. 2013;8(10):e78493. DOI: 10.1371/journal.pone.0078493

259

Yuan J, Ding R, Wang L, Sheng L, Li J, Hu D. Screening for depression in acute coronary syndrome patients: A comparison of Patient Health Questionnaire-9 versus Hospital Anxiety and Depression Scale-Depression. Journal of Psychosomatic Research. 2019;121:24–8. DOI: 10.1016/j.jpsychores.2019.03.018

260

Frasure-Smith N, Lespérance F. Depression and Anxiety as Predictors of 2-Year Cardiac Events in Patients With Stable Coronary Artery Disease. Archives of General Psychiatry. 2008;65(1):62–71. DOI: 10.1001/archgenpsychiatry.2007.4

261

Harshfield EL, Pennells L, Schwartz JE, Willeit P, Kaptoge S, Bell S et al. Association Between Depressive Symptoms and Incident Cardiovascular Diseases. JAMA. 2020;324(23):2396–405. DOI: 10.1001/jama.2020.23068

262

Lee SN, Yun J-S, Ko S-H, Ahn Y-B, Yoo K-D, Her S-H et al. Impacts of gender and lifestyle on the association between depressive symptoms and cardiovascular disease risk in the UK Biobank. Scientific Reports. 2023;13(1):10758. DOI: 10.1038/s41598-023-37221-x

263

Rajan S, McKee M, Rangarajan S, Bangdiwala S, Rosengren A, Gupta R et al. Association of Symptoms of Depression With Cardiovascular Disease and Mortality in Low-, Middle-, and High-Income Countries. JAMA Psychiatry. 2020;77(10):1052–63. DOI: 10.1001/jamapsychiatry.2020.1351

264

Chen X, Liu Z, Yang Y, Chen G, Wan Q, Qin G et al. Depression Status, Lifestyle, and Metabolic Factors With Subsequent Risk for Major Cardiovascular Events: The China Cardiometabolic Disease and Cancer Cohort (4C) Study. Frontiers in Cardiovascular Medicine. 2022;9:865063. DOI: 10.3389/fcvm.2022.865063

265

Wei J, Hou R, Zhang X, Xu H, Xie L, Chandrasekar EK et al. The association of late-life depression with all-cause and cardiovascular mortality among community-dwelling older adults: systematic review and meta-analysis. British Journal of Psychiatry. 2019;215(2):449–55. DOI: 10.1192/bjp.2019.74

266

Krittanawong C, Maitra NS, Qadeer YK, Wang Z, Fogg S, Storch EA et al. Association of Depression and Cardiovascular Disease. The American Journal of Medicine. 2023;136(9):881–95. DOI: 10.1016/j.amjmed.2023.04.036

267

Katzmann J, Mahfoud F, Böhm M, Schulz M, Laufs U. Association of medication adherence and depression with the control of low-density lipoprotein cholesterol and blood pressure in patients at high cardiovascular risk. Patient Preference and Adherence. 2018;13:9–19. DOI: 10.2147/PPA.S182765

268

Hamieh N, Kab S, Zins M, Blacher J, Meneton P, Empana J-P et al. Depressive symptoms and non-adherence to treatable cardiovascular risk factors’ medications in the CONSTANCES cohort. European Heart Journal - Cardiovascular Pharmacotherapy. 2021;7(4):280–6. DOI: 10.1093/ehjcvp/pvaa124

269

Colquhoun D, Malawaraarachchi N, Ferreira-Jardim A. Poor adherence to anticoagulant therapy: a call to screen and treat depression in patients with atrial fibrillation. Heart, Lung and Circulation. 2015;24:S389–90. DOI: 10.1016/j.hlc.2015.06.646

270

Crawshaw J, Auyeung V, Norton S, Weinman J. Identifying psychosocial predictors of medication non-adherence following acute coronary syndrome: A systematic review and meta-analysis. Journal of Psychosomatic Research. 2016;90:10–32. DOI: 10.1016/j.jpsychores.2016.09.003

271

Grenard JL, Munjas BA, Adams JL, Suttorp M, Maglione M, McGlynn EA et al. Depression and Medication Adherence in the Treatment of Chronic Diseases in the United States: A Meta-Analysis. Journal of General Internal Medicine. 2011;26(10):1175–82. DOI: 10.1007/s11606-011-1704-y

272

Gonzalez JS, Peyrot M, McCarl LA, Collins EM, Serpa L, Mimiaga MJ et al. Depression and Diabetes Treatment Nonadherence: A Meta-Analysis. Diabetes Care. 2008;31(12):2398–403. DOI: 10.2337/dc08-1341

273

Poletti V, Pagnini F, Banfi P, Volpato E. The Role of Depression on Treatment Adherence in Patients with Heart Failure – a Systematic Review of the Literature. Current Cardiology Reports. 2022;24(12):1995–2008. DOI: 10.1007/s11886-022-01815-0

274

VA/DoD Clinical Practice Guideline. (2022). The Management of Major Depressive Disorder. Washington, DC: U.S. Government Printing Office. 2022. 160p. Av. at: https://www.healthquality.va.gov/guidelines/MH/mdd/VADODMDDCPGFinal508.pdf

275

Lewis G, Marston L, Duffy L, Freemantle N, Gilbody S, Hunter R et al. Maintenance or Discontinuation of Antidepressants in Primary Care. New England Journal of Medicine. 2021;385(14):1257–67. DOI: 10.1056/NEJMoa2106356

276

Kato M, Hori H, Inoue T, Iga J, Iwata M, Inagaki T et al. Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. Molecular Psychiatry. 2021;26(1):118–33. DOI: 10.1038/s41380-020-0843-0

277

Zhou D, Lv Z, Shi L, Zhou X, Lin Q, Chen X et al. Effects of antidepressant medicines on preventing relapse of unipolar depression: a pooled analysis of parametric survival curves. Psychological Medicine. 2022;52(1):48–56. DOI: 10.1017/S0033291720001610

278

Liu X, Momen NC, Molenaar N, Rommel A-S, Bergink V, Munk-Olsen T. Discontinuation of antidepressants: Is there a minimum time on treatment that will reduce relapse risk? Journal of Affective Disorders. 2021;290:254–60. DOI: 10.1016/j.jad.2021.04.045

279

Safren SA, Gonzalez JS, Wexler DJ, Psaros C, Delahanty LM, Blashill AJ et al. A Randomized Controlled Trial of Cognitive Behavioral Therapy for Adherence and Depression (CBT-AD) in Patients With Uncontrolled Type 2 Diabetes. Diabetes Care. 2014;37(3):625–33. DOI: 10.2337/dc13-0816

280

Kronish IM, Rieckmann N, Burg MM, Edmondson D, Schwartz JE, Davidson KW. The effect of enhanced depression care on adherence to risk-reducing behaviors after acute coronary syndromes: Findings from the COPES trial. American Heart Journal. 2012;164(4):524–9. DOI: 10.1016/j.ahj.2012.07.024

281

Bauer LK, Caro MA, Beach SR, Mastromauro CA, Lenihan E, Januzzi JL et al. Effects of Depression and Anxiety Improvement on Adherence to Medication and Health Behaviors in Recently Hospitalized Cardiac Patients. The American Journal of Cardiology. 2012;109(9):1266–71. DOI: 10.1016/j.amjcard.2011.12.017

282

Rohde C, Knudsen JS, Schmitz N, Østergaard SD, Thomsen RW. The impact of hospital-diagnosed depression or use of antidepressants on treatment initiation, adherence and HbA1c/LDL target achievement in newly diagnosed type 2 diabetes. Diabetologia. 2021;64(2):361–74. DOI: 10.1007/s00125-020-05303-4

283

Kariis HM, Kasela S, Jürgenson T, Saar A, Lass J, Krebs K et al. The role of depression and antidepressant treatment in antihypertensive medication adherence and persistence: Utilising electronic health record data. Journal of Psychiatric Research. 2023;168:269–78. DOI: 10.1016/j.jpsychires.2023.10.018

284

Leung LB, Chu K, Rose D, Stockdale S, Post EP, Wells KB et al. Electronic Population-Based Depression Detection and Management Through Universal Screening in the Veterans Health Administration. JAMA Network Open. 2022;5(3):e221875. DOI: 10.1001/jamanetworkopen.2022.1875

285

Brinck-Claussen UØ, Curth NK, Christensen KS, Davidsen AS, Mikkelsen JH, Lau ME et al. Improving the precision of depression diagnosis in general practice: a cluster-randomized trial. BMC Family Practice. 2021;22(1):88. DOI: 10.1186/s12875-021-01432-w

286

Löwe B, Scherer M, Braunschneider L-E, Marx G, Eisele M, Mallon T et al. Clinical effectiveness of patient-targeted feedback following depression screening in general practice (GET.FEEDBACK.GP): an investigator-initiated, prospective, multicentre, three-arm, observerblinded, randomised controlled trial in Germany. The Lancet Psychiatry. 2024;11(4):262–73. DOI: 10.1016/S2215-0366(24)00035-X

287

Wang J, Wu X, Lai W, Long E, Zhang X, Li W et al. Prevalence of depression and depressive symptoms among outpatients: a systematic review and meta-analysis. BMJ Open. 2017;7(8):e017173. DOI: 10.1136/bmjopen-2017-017173

288

Moradi Y, Albatineh AN, Mahmoodi H, Gheshlagh RG. The relationship between depression and risk of metabolic syndrome: a meta‐analysis of observational studies. Clinical Diabetes and Endocrinology. 2021;7(1):4. DOI: 10.1186/s40842-021-00117-8

289

Amare AT, Schubert KO, Klingler-Hoffmann M, Cohen-Woods S, Baune BT. The genetic overlap between mood disorders and cardiometabolic diseases: a systematic review of genome wide and candidate gene studies. Translational Psychiatry. 2017;7(1):e1007. DOI: 10.1038/tp.2016.261

290

Lapa ME, Swabe GM, Magnani JW. Association of Depression and Adherence to Oral Anticoagulation in Patients With Atrial Fibrillation. Journal of the American Heart Association. 2023;12(22):e031281. DOI: 10.1161/JAHA.123.031281

291

Gathright EC, Dolansky MA, Gunstad J, Redle JD, Josephson RA, Moore SM et al. The impact of medication nonadherence on the relationship between mortality risk and depression in heart failure. Health Psychology. 2017;36(9):839–47. DOI: 10.1037/hea0000529

292

Herring MP. Effect of Exercise Training on Depressive Symptoms Among Patients With a Chronic Illness: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Archives of Internal Medicine. 2012;172(2):101–11. DOI: 10.1001/archinternmed.2011.696

293

Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet. 2018;391(10128):1357–66. DOI: 10.1016/S0140-6736(17)32802-7

294

Strawbridge R, Carter B, Marwood L, Bandelow B, Tsapekos D, Nikolova VL et al. Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis. British Journal of Psychiatry. 2019;214(1):42–51. DOI: 10.1192/bjp.2018.233

295

Davies P, Ijaz S, Williams CJ, Kessler D, Lewis G, Wiles N. Pharmacological interventions for treatment-resistant depression in adults. Cochrane Database of Systematic Reviews. 2019;12:CD010557. DOI: 10.1002/14651858.CD010557.pub2

296

Li C-T, Bai Y-M, Huang Y-L, Chen Y-S, Chen T-J, Cheng J-Y et al. Association between antidepressant resistance in unipolar depression and subsequent bipolar disorder: cohort study. British Journal of Psychiatry. 2012;200(1):45–51. DOI: 10.1192/bjp. bp.110.086983

297

VA/DOD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder And Acute Stress Disorder. Version 4.0. 2023. 167p. Av. at: https://www.healthquality.va.gov/guidelines/MH/ptsd/VA-DoD-CPG-PTSD-Full-CPG-Edited-11162024.pdf

298

Phelps AJ, Lethbridge R, Brennan S, Bryant RA, Burns P, Cooper JA et al. Australian guidelines for the prevention and treatment of posttraumatic stress disorder: Updates in the third edition. Australian & New Zealand Journal of Psychiatry. 2022;56(3):230–47. DOI: 10.1177/00048674211041917

299

American Psychological Association. Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder (PTSD) in Adults. 2017. 119p. Av. at: https://www.apa.org/ptsd-guideline/ptsd.pdf

300

Coventry PA, Meader N, Melton H, Temple M, Dale H, Wright K et al. Psychological and pharmacological interventions for posttraumatic stress disorder and comorbid mental health problems following complex traumatic events: Systematic review and component network meta-analysis. PLOS Medicine. 2020;17(8):e1003262. DOI: 10.1371/journal.pmed.1003262

301

Lewis C, Roberts NP, Andrew M, Starling E, Bisson JI. Psychological therapies for posttraumatic stress disorder in adults: systematic review and meta-analysis. European Journal of Psychotraumatology. 2020;11(1):1729633. DOI: 10.1080/20008198.2020.1729633

302

Merz J, Schwarzer G, Gerger H. Comparative Efficacy and Acceptability of Pharmacological, Psychotherapeutic, and Combination Treatments in Adults With Posttraumatic Stress Disorder: A Network Metaanalysis. JAMA Psychiatry. 2019;76(9):904–13. DOI: 10.1001/jamapsychiatry.2019.0951

303

Lee DJ, Schnitzlein CW, Wolf JP, Vythilingam M, Rasmusson AM, Hoge CW. Psychotherapy versus pharmacotherapy for posttraumatic stress disorder: systemic review and meta-analyses to determine firstline treatments. Depression and Anxiety. 2016;33(9):792–806. DOI: 10.1002/da.22511

304

Beristianos MH, Yaffe K, Cohen B, Byers AL. PTSD and Risk of Incident Cardiovascular Disease in Aging Veterans. The American Journal of Geriatric Psychiatry. 2016;24(3):192–200. DOI: 10.1016/j.jagp.2014.12.003

305

Roer GE, Lien L, Bolstad I, Aaseth JO, Abebe DS. The impact of PTSD on risk of cardiometabolic diseases: a national patient cohort study in Norway. BMC Psychiatry. 2023;23(1):349. DOI: 10.1186/s12888-023-04866-x

306

Gradus JL, Farkas DK, Svensson E, Ehrenstein V, Lash TL, Milstein A et al. Associations between stress disorders and cardiovascular disease events in the Danish population. BMJ Open. 2015;5(12):e009334. DOI: 10.1136/bmjopen-2015-009334

307

Rauch SAM, Kim HM, Powell C, Tuerk PW, Simon NM, Acierno R et al. Efficacy of Prolonged Exposure Therapy, Sertraline Hydrochloride, and Their Combination Among Combat Veterans With Posttraumatic Stress Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2019;76(2):117–26. DOI: 10.1001/jamapsychiatry.2018.3412

308

Zoellner LA, Roy-Byrne PP, Mavissakalian M, Feeny NC. Doubly Randomized Preference Trial of Prolonged Exposure Versus Sertraline for Treatment of PTSD. American Journal of Psychiatry. 2019;176(4):287–96. DOI: 10.1176/appi.ajp.2018.17090995

309

Williams T, Phillips NJ, Stein DJ, Ipser JC. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database of Systematic Reviews. 2022;3(3):CD002795. DOI: 10.1002/14651858.CD002795.pub3

310

Cipriani A, Williams T, Nikolakopoulou A, Salanti G, Chaimani A, Ipser J et al. Comparative efficacy and acceptability of pharmacological treatments for posttraumatic stress disorder in adults: a network meta-analysis. Psychological Medicine. 2018;48(12):1975–84. DOI: 10.1017/S003329171700349X

311

De Moraes Costa G, Zanatta FB, Ziegelmann PK, Soares Barros AJ, Mello CF. Pharmacological treatments for adults with posttraumatic stress disorder: A network meta-analysis of comparative efficacy and acceptability. Journal of Psychiatric Research. 2020;130:412–20. DOI: 10.1016/j.jpsychires.2020.07.046

312

LeardMann CA, Kelton ML, Smith B, Littman AJ, Boyko EJ, Wells TS et al. Prospectively Assessed Posttraumatic Stress Disorder and Associated Physical Activity. Public Health Reports®. 2011;126(3):371–83. DOI: 10.1177/003335491112600311

313

Jadhakhan F, Lambert N, Middlebrook N, Evans DW, Falla D. Is exercise/physical activity effective at reducing symptoms of posttraumatic stress disorder in adults – A systematic review. Frontiers in Psychology. 2022;13:943479. DOI: 10.3389/fpsyg.2022.943479

314

Björkman F, Ekblom Ö. Physical Exercise as Treatment for PTSD: A Systematic Review and Meta-Analysis. Military Medicine. 2022;187(9–10):e1103–13. DOI: 10.1093/milmed/usab497

315

Guina J, Rossetter SR, DeRHODES BJ, Nahhas RW, Welton RS. Benzodiazepines for PTSD: A Systematic Review and Meta-Analysis. Journal of Psychiatric Practice. 2015;21(4):281–303. DOI: 10.1097/PRA.0000000000000091

316

Gates MA, Holowka DW, Vasterling JJ, Keane TM, Marx BP, Rosen RC. Posttraumatic stress disorder in veterans and military personnel: Epidemiology, screening, and case recognition. Psychological Services. 2012;9(4):361–82. DOI: 10.1037/a0027649

317

Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. European Neuropsychopharmacology. 2011;21(9):655–79. DOI: 10.1016/j.euroneuro.2011.07.018

318

Huo N, Vemuri P, Graff-Radford J, Syrjanen J, Machulda M, Knopman DS et al. Sex Differences in the Association Between Midlife Cardiovascular Conditions or Risk Factors With Midlife Cognitive Decline. Neurology. 2022;98(6):e623–32. DOI: 10.1212/WNL.0000000000013174

319

Liang X, Huang Y, Han X. Associations between coronary heart disease and risk of cognitive impairment: A meta‐analysis. Brain and Behavior. 2021;11(5):e02108. DOI: 10.1002/brb3.2108

320

Adelborg K, Horváth‐Puhó E, Ording A, Pedersen L, Sørensen HT, Henderson VW. Heart failure and risk of dementia: a Danish nationwide population‐based cohort study. European Journal of Heart Failure. 2017;19(2):253–60. DOI: 10.1002/ejhf.631

321

Mulligan MD, Murphy R, Reddin C, Judge C, Ferguson J, Alvarez-Iglesias A et al. Population attributable fraction of hypertension for dementia: global, regional, and national estimates for 186 countries. eClinicalMedicine. 2023;60:102012. DOI: 10.1016/j.eclinm.2023.102012

322

Zuin M, Roncon L, Passaro A, Bosi C, Cervellati C, Zuliani G. Risk of dementia in patients with atrial fibrillation: Short versus long follow‐up. A systematic review and meta‐analysis. International Journal of Geriatric Psychiatry. 2021;36(10):1488–500. DOI: 10.1002/gps.5582

323

Kuźma E, Lourida I, Moore SF, Levine DA, Ukoumunne OC, Llewellyn DJ. Stroke and dementia risk: A systematic review and meta‐analysis. Alzheimer’s & Dementia. 2018;14(11):1416–26. DOI: 10.1016/j.jalz.2018.06.3061

324

Lee W, Kang S, Kim S, Lee S, Myung W, Jheon K et al. Impact of dementia and drug compliance on patients with acute myocardial infarction. Clinical Cardiology. 2023;46(10):1253–9. DOI: 10.1002/clc.24091

325

El-Saifi N, Moyle W, Jones C, Tuffaha H. Medication Adherence in Older Patients With Dementia: A Systematic Literature Review. Journal of Pharmacy Practice. 2018;31(3):322–34. DOI: 10.1177/0897190017710524

326

Cho MH, Shin DW, Chang S-A, Lee JE, Jeong S-M, Kim SH et al. Association between cognitive impairment and poor antihypertensive medication adherence in elderly hypertensive patients without dementia. Scientific Reports. 2018;8(1):11688. DOI: 10.1038/s41598-018-29974-7

327

Dolansky MA, Hawkins MAW, Schaefer JT, Sattar A, Gunstad J, Redle JD et al. Association Between Poorer Cognitive Function and Reduced Objectively Monitored Medication Adherence in Patients With Heart Failure. Circulation: Heart Failure. 2016;9(12):e002475. DOI: 10.1161/CIRCHEARTFAILURE.116.002475

328

Patnode CD, Perdue LA, Rossom RC, Rushkin MC, Redmond N, Thomas RG et al. Screening for Cognitive Impairment in Older Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2020;323(8):764–85. DOI: 10.1001/jama.2019.22258

329

Ngandu T, Lehtisalo J, Solomon A, Levälahti E, Ahtiluoto S, Antikainen R et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. The Lancet. 2015;385(9984):2255–63. DOI: 10.1016/S0140-6736(15)60461-5

330

Na R, Yang J, Yeom Y, Kim YJ, Byun S, Kim K et al. A Systematic Review and Meta-Analysis of Nonpharmacological Interventions for Moderate to Severe Dementia. Psychiatry Investigation. 2019;16(5):325–35. DOI: 10.30773/pi.2019.02.11.2

331

Zhou S, Chen S, Liu X, Zhang Y, Zhao M, Li W. Physical Activity Improves Cognition and Activities of Daily Living in Adults with Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. International Journal of Environmental Research and Public Health. 2022;19(3):1216. DOI: 10.3390/ijerph19031216

332

Ornish D, Madison C, Kivipelto M, Kemp C, McCulloch CE, Galasko D et al. Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer’s disease: a randomized, controlled clinical trial. Alzheimer’s Research & Therapy. 2024;16(1):122. DOI: 10.1186/s13195-024-01482-z

333

Woods B, Rai HK, Elliott E, Aguirre E, Orrell M, Spector A. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database of Systematic Reviews. 2023;1:CD005562. DOI: 10.1002/14651858.CD005562.pub3

334

Kudlicka A, Martyr A, Bahar-Fuchs A, Sabates J, Woods B, Clare L. Cognitive rehabilitation for people with mild to moderate dementia. Cochrane Database of Systematic Reviews. 2023;6:CD013388. DOI: 10.1002/14651858.CD013388.pub2

335

Bahar-Fuchs A, Martyr A, Goh AM, Sabates J, Clare L. Cognitive training for people with mild to moderate dementia. Cochrane Database of Systematic Reviews. 2019;3:CD013069. DOI: 10.1002/14651858.CD013069.pub2

336

Saragih ID, Tonapa SI, Saragih IS, Lee BO. Effects of cognitive stimulation therapy for people with dementia: A systematic review and meta-analysis of randomized controlled studies. International Journal of Nursing Studies. 2022;128:104181. DOI: 10.1016/j.ijnurstu.2022.104181

337

Kishi T, Matsunaga S, Oya K, Nomura I, Ikuta T, Iwata N. Memantine for Alzheimer’s Disease: An Updated Systematic Review and Meta-analysis. Journal of Alzheimer’s Disease. 2017;60(2):401–25. DOI: 10.3233/JAD-170424

338

McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE et al. Memantine for dementia. Cochrane Database of Systematic Reviews. 2019;3:CD003154. DOI: 10.1002/14651858.CD003154.pub6

339

Birks JS, Grimley Evans J. Rivastigmine for Alzheimer’s disease. Cochrane Database of Systematic Reviews. 2015;4:CD001191. DOI: 10.1002/14651858.CD001191.pub3

340

Rojas-Fernandez CH. Little evidence that cholinesterase inhibitors prevent progression of mild cognitive impairment to dementia, but they are associated with adverse effects. Evidence Based Mental Health. 2013;16(2):39. DOI: 10.1136/eb-2012-101087

341

Vaci N, Koychev I, Kim CH, Kormilitzin A, Liu Q, Lucas C et al. Real-world effectiveness, its predictors and onset of action of cholinesterase inhibitors and memantine in dementia: retrospective health record study. The British Journal of Psychiatry. 2021;218(5):261–7. DOI: 10.1192/bjp.2020.136

342

Гаврилова С.И., Колыхалов И.В., Михайлова Н.М., Пономарева Е.В., Федорова Я.Б., Медведев В.Э. и др. Многоцентровое открытое сравнительное рандомизированное исследование эффективности и безопасности применения препарата Акатинол Мемантин, 20 мг (однократный прием) в сравнении с препаратом Акатинол Мемантин, 10 мг (двукратный прием) у пациентов с сосудистой деменцией. Журнал неврологии и психиатрии им. С.С. Корсакова. 2024;124(2):69–77. DOI: 10.17116/jnevro202412402169

Gavrilova S.I., Kolykhalov I.V., Mikhaylova N.M., Ponomareva E.V., Fedorova Ya.B., Medvedev V.E. et al. Multicenter open comparative randomized study of efficacy and safety of Akatinol Memantine 20 mg (single-doses) vs Akatinol Memantine 10 mg (double-doses) in patients with vascular dementia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(2):69–77. DOI: 10.17116/jnevro202412402169

343

Parish S, Mafham M, Offer A, Barton J, Wallendszus K, Stevens W et al. Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial. European Heart Journal. 2022;43(21):2010–9. DOI: 10.1093/eurheartj/ehac179

344

Tao T, Feng G, Fang Y. Association between aspirin use and risk of dementia: a systematic review and meta-analysis. European Geriatric Medicine. 2023;15(1):3–18. DOI: 10.1007/s41999-023-00877-9

345

McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database of Systematic Reviews. 2016;1:CD003160. DOI: 10.1002/14651858.CD003160.pub3

346

Davis KAS, Bishara D, Perera G, Molokhia M, Rajendran L, Stewart RJ. Benefits and Harms of Statins in People with Dementia: A Systematic Review and Meta‐Analysis. Journal of the American Geriatrics Society. 2020;68(3):650–8. DOI: 10.1111/jgs.16342

347

Olmastroni E, Molari G, De Beni N, Colpani O, Galimberti F, Gazzotti M et al. Statin use and risk of dementia or Alzheimer’s disease: a systematic review and meta-analysis of observational studies. European Journal of Preventive Cardiology. 2022;29(5):804–14. DOI: 10.1093/eurjpc/zwab208

348

Zhou Z, Ryan J, Ernst ME, Zoungas S, Tonkin AM, Woods RL et al. Effect of Statin Therapy on Cognitive Decline and Incident Dementia in Older Adults. Journal of the American College of Cardiology. 2021;77(25):3145–56. DOI: 10.1016/j.jacc.2021.04.075

349

Jack CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimer’s & Dementia. 2024;20(8):5143–69. DOI: 10.1002/alz.13859

350

Meijer A, Conradi HJ, Bos EH, Anselmino M, Carney RM, Denollet J et al. Adjusted prognostic association of depression following myocardial infarction with mortality and cardiovascular events: individual patient data meta-analysis. British Journal of Psychiatry. 2013;203(2):90–102. DOI: 10.1192/bjp.bp.112.111195

351

Doyle F, McGee H, Conroy R, Conradi HJ, Meijer A, Steeds R et al. Systematic Review and Individual Patient Data Meta-Analysis of Sex Differences in Depression and Prognosis in Persons With Myocardial Infarction: A MINDMAPS Study. Psychosomatic Medicine. 2015;77(4):419–28. DOI: 10.1097/PSY.0000000000000174

352

Roest AM, Martens EJ, Denollet J, De Jonge P. Prognostic Association of Anxiety Post Myocardial Infarction With Mortality and New Cardiac Events: A Meta-Analysis. Psychosomatic Medicine. 2010;72(6):563–9. DOI: 10.1097/PSY.0b013e3181dbff97

353

Kronish IM, Edmondson D, Moise N, Chang BP, Wei Y, Veneros DL et al. Posttraumatic stress disorder in patients who rule out versus rule in for acute coronary syndrome. General Hospital Psychiatry. 2018;53:101–7. DOI: 10.1016/j.genhosppsych.2018.02.007

354

Edmondson D, Richardson S, Falzon L, Davidson KW, Mills MA, Neria Y. Posttraumatic Stress Disorder Prevalence and Risk of Recurrence in Acute Coronary Syndrome Patients: A Meta-analytic Review. PLoS ONE. 2012;7(6):e38915. DOI: 10.1371/journal.pone.0038915

355

Dong Z, Yang Q, Chen H. Estimating the prevalence of depression in people with acute coronary syndromes: A systematic review and meta-analysis. Medicine. 2024;103(17):e37906. DOI: 10.1097/MD.0000000000037906

356

Gustad LT, Laugsand LE, Janszky I, Dalen H, Bjerkeset O. Symptoms of anxiety and depression and risk of acute myocardial infarction: the HUNT 2 study. European Heart Journal. 2014;35(21):1394–403. DOI: 10.1093/eurheartj/eht387

357

Rosengren A, Hawken S, Ôunpuu S, Sliwa K, Zubaid M, Almahmeed WA et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11 119 cases and 13 648 controls from 52 countries (the INTERHEART study): case-control study. The Lancet. 2004;364(9438):953–62. DOI: 10.1016/S0140-6736(04)17019-0

358

Scherrer JF, Chrusciel T, Zeringue A, Garfield LD, Hauptman PJ, Lustman PJ et al. Anxiety disorders increase risk for incident myocardial infarction in depressed and nondepressed Veterans Administration patients. American Heart Journal. 2010;159(5):772–9. DOI: 10.1016/j.ahj.2010.02.033

359

Chen Y-H, Tsai S-Y, Lee H-C, Lin H-C. Increased Risk of Acute Myocardial Infarction for Patients With Panic Disorder: A Nationwide Population-Based Study. Psychosomatic Medicine. 2009;71(7):798–804. DOI: 10.1097/PSY.0b013e3181ad55e3

360

Flygare O, Boberg J, Rück C, Hofmann R, Leosdottir M, MataixCols D et al. Association of anxiety or depression with risk of recurrent cardiovascular events and death after myocardial infarction: A nationwide registry study. International Journal of Cardiology. 2023;381:120–7. DOI: 10.1016/j.ijcard.2023.04.023

361

Myers V, Gerber Y, Benyamini Y, Goldbourt U, Drory Y. Post-myocardial infarction depression: Increased hospital admissions and reduced adoption of secondary prevention measures – A longitudinal study. Journal of Psychosomatic Research. 2012;72(1):5–10. DOI: 10.1016/j.jpsychores.2011.09.009

362

Kim J-M, Stewart R, Bae K-Y, Kang H-J, Kim S-W, Shin I-S et al. Effects of depression comorbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine. 2015;45(8):1641–52. DOI: 10.1017/S003329171400275X

363

Kim J-M, Stewart R, Lee Y-S, Lee H-J, Kim MC, Kim J-W et al. Effect of Escitalopram vs Placebo Treatment for Depression on Longterm Cardiac Outcomes in Patients With Acute Coronary Syndrome: A Randomized Clinical Trial. JAMA. 2018;320(4):350–8. DOI: 10.1001/jama.2018.9422

364

Glassman AH, O’Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT Jr et al. Sertraline Treatment of Major Depression in Patients With Acute MI or Unstable Angina. JAMA. 2002;288(6):701–9. DOI: 10.1001/jama.288.6.701

365

Van Melle JP, De Jonge P, Honig A, Schene AH, Kuyper AMG, Crijns HJGM et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry. 2007;190(6):460–6. DOI: 10.1192/bjp.bp.106.028647

366

Berkman LF, Blumenthal J, Burg M, Carney RM, Catellier D, Cowan MJ et al. Effects of Treating Depression and Low Perceived Social Support on Clinical Events After Myocardial Infarction: The Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA. 2003;289(23):3106–16. DOI: 10.1001/jama.289.23.3106

367

Abdullah A, Eigbire G, Salama A, Wahab A, Awadalla M, Hoefen R et al. Impact of delirium on patients hospitalized for myocardial infarction: A propensity score analysis of the National Inpatient Sample. Clinical Cardiology. 2018;41(7):910–5. DOI: 10.1002/clc.22972

368

Jäckel M, Zotzmann V, Wengenmayer T, Duerschmied D, Biever PM, Spieler D et al. Incidence and predictors of delirium on the intensive care unit after acute myocardial infarction, insight from a retrospective registry. Catheterization and Cardiovascular Interventions. 2021;98(6):1072–81. DOI: 10.1002/ccd.29275

369

Patil S, Gonuguntala K, Rojulpote C, Kumar M, Corradi JP, Chen K. Delirium is an important predictor of mortality in elderly patients with ST-elevation myocardial infarction: insight from National Inpatient Sample database. Coronary Artery Disease. 2020;31(8):665–70. DOI: 10.1097/MCA.0000000000000978

370

Kang H-J, Stewart R, Bae K-Y, Kim S-W, Shin I-S, Hong YJ et al. Effects of depression screening on psychiatric outcomes in patients with acute coronary syndrome: Findings from the K-DEPACS and EsDEPACS studies. International Journal of Cardiology. 2015;190:114–21. DOI: 10.1016/j.ijcard.2015.04.164

371

Kronish IM, Moise N, Cheung YK, Clarke GN, Dolor RJ, Duer-Hefele J et al. Effect of Depression Screening After Acute Coronary Syndromes on Quality of Life: The CODIACS-QoL Randomized Clinical Trial. JAMA Internal Medicine. 2020;180(1):45–53. DOI: 10.1001/jamainternmed.2019.4518

372

Ladapo JA, Davidson KW, Moise N, Chen A, Clarke GN, Dolor RJ et al. Economic outcomes of depression screening after acute coronary syndromes: The CODIACS-QoL randomized clinical trial. General Hospital Psychiatry. 2021;71:47–54. DOI: 10.1016/j.genhosppsych.2021.04.001

373

Sweda R, Siontis GCM, Nikolakopoulou A, Windecker S, Pilgrim T. Antidepressant treatment in patients following acute coronary syndromes: a systematic review and Bayesian meta‐analysis. ESC Heart Failure. 2020;7(6):3610–20. DOI: 10.1002/ehf2.12861

374

Li J, Ji F, Song J, Gao X, Jiang D, Chen G et al. Anxiety and clinical outcomes of patients with acute coronary syndrome: a metaanalysis. BMJ Open. 2020;10(7):e034135. DOI: 10.1136/bmjopen-2019-034135

375

Honkola J, Hookana E, Malinen S, Kaikkonen KS, Junttila MJ, Isohanni M et al. Psychotropic medications and the risk of sudden cardiac death during an acute coronary event. European Heart Journal. 2012;33(6):745–51. DOI: 10.1093/eurheartj/ehr368

376

Ben-Shoshan J, Segman-Rosenstveig Y, Arbel Y, Chorin E, Barkagan M, Rozenbaum Z et al. Comparison of Triggering and Nontriggering Factors in ST-Segment Elevation Myocardial Infarction and Extent of Coronary Arterial Narrowing. The American Journal of Cardiology. 2016;117(8):1219–23. DOI: 10.1016/j.amjcard.2016.01.038

377

Tofler GH, Kopel E, Klempfner R, Eldar M, Buckley T, Goldenberg I. Triggers and Timing of Acute Coronary Syndromes. The American Journal of Cardiology. 2017;119(10):1560–5. DOI: 10.1016/j.amjcard.2017.02.022

378

Chan B, Buckley T, Tofler GH. Emotional Stress and Physical Exertion as Triggers of Acute Myocardial Infarction. The American Journal of Cardiology. 2023;203:285–7. DOI: 10.1016/j.amjcard.2023.07.085

379

Steptoe A, Strike PC, Perkins-Porras L, McEwan JR, Whitehead DL. Acute Depressed Mood as a Trigger of Acute Coronary Syndromes. Biological Psychiatry. 2006;60(8):837–42. DOI: 10.1016/j.biopsych.2006.03.041

380

Smyth A, O’Donnell M, Lamelas P, Teo K, Rangarajan S, Yusuf S. Physical Activity and Anger or Emotional Upset as Triggers of Acute Myocardial Infarction: The INTERHEART Study. Circulation. 2016;134(15):1059–67. DOI: 10.1161/CIRCULATIONAHA.116.023142

381

Lissåker CT, Norlund F, Wallert J, Held C, Olsson EM. Persistent emotional distress after a first-time myocardial infarction and its association to late cardiovascular and non-cardiovascular mortality. European Journal of Preventive Cardiology. 2019;26(14):1510–8. DOI: 10.1177/2047487319841475

382

Shang J, Dong J, Zhu S, Chen Q, Hua J. Trends in cognitive function before and after myocardial infarction: findings from the China Health and Retirement Longitudinal Study. Frontiers in Aging Neuroscience. 2024;16:1283997. DOI: 10.3389/fnagi.2024.1283997

383

Johansen MC, Ye W, Gross A, Gottesman RF, Han D, Whitney R et al. Association Between Acute Myocardial Infarction and Cognition. JAMA Neurology. 2023;80(7):723–31. DOI: 10.1001/jamaneurol.2023.1331

384

Park Y, Bateman BT, Kim DH, Hernandez-Diaz S, Patorno E, Glynn RJ et al. Use of haloperidol versus atypical antipsychotics and risk of inhospital death in patients with acute myocardial infarction: cohort study. BMJ. 2018;360:k1218. DOI: 10.1136/bmj.k1218

385

Белялов Ф.И. Депрессия, тревога и стресс у пациентов с ишемической болезнью сердца. Терапевтический архив. 2017;89(8):104–9. DOI: 10.17116/terarkh2017898104-109

Belialov F.I. Depression, anxiety, and stress in patients with coronary heart disease. Therapeutic Archive. 2017;89(8):104–9. DOI: 10.17116/terarkh2017898104-109

386

Edmondson D, Kronish IM, Shaffer JA, Falzon L, Burg MM. Posttraumatic stress disorder and risk for coronary heart disease: A meta-analytic review. American Heart Journal. 2013;166(5):806–14. DOI: 10.1016/j.ahj.2013.07.031

387

Kemp AH, Brunoni AR, Nunes MA, Santos IS, Goulart AC, Ribeiro AL et al. The association between mood and anxiety disorders, and coronary heart disease in Brazil: a cross-sectional analysis on the Brazilian longitudinal study of adult health (ELSA-Brasil). Frontiers in Psychology. 2015;6:187. DOI: 10.3389/fpsyg.2015.00187

388

Gan Y, Gong Y, Tong X, Sun H, Cong Y, Dong X et al. Depression and the risk of coronary heart disease: a meta-analysis of prospective cohort studies. BMC Psychiatry. 2014;14(1):371. DOI: 10.1186/s12888-014-0371-z

389

Poole L, Steptoe A. Depressive symptoms predict incident chronic disease burden 10 years later: Findings from the English Longitudinal Study of Ageing (ELSA). Journal of Psychosomatic Research. 2018;113:30–6. DOI: 10.1016/j.jpsychores.2018.07.009

390

Herbst S, Pietrzak RH, Wagner J, White WB, Petry NM. Lifetime Major Depression is Associated With Coronary Heart Disease in Older Adults: Results From the National Epidemiologic Survey on Alcohol and Related Conditions. Psychosomatic Medicine. 2007;69(8):729–34. DOI: 10.1097/PSY.0b013e3181574977

391

Roest AM, Martens EJ, de Jonge P, Denollet J. Anxiety and Risk of Incident Coronary Heart Disease: A Meta-Analysis. Journal of the American College of Cardiology. 2010;56(1):38–46. DOI: 10.1016/j.jacc.2010.03.034

392

Emdin CA, Odutayo A, Wong CX, Tran J, Hsiao AJ, Hunn BHM. Meta-Analysis of Anxiety as a Risk Factor for Cardiovascular Disease. The American Journal of Cardiology. 2016;118(4):511–9. DOI: 10.1016/j.amjcard.2016.05.041

393

Tully PJ, Turnbull DA, Beltrame J, Horowitz J, Cosh S, Baumeister H et al. Panic disorder and incident coronary heart disease: a systematic review and meta-regression in 1 131 612 persons and 58 111 cardiac events. Psychological Medicine. 2015;45(14):2909–20. DOI: 10.1017/S0033291715000963

394

Derisi MM, Nasiri MJ, Aryan A, Moosavi Jarrahi A, Amiri P, Mohseny M. Prevalence of psychiatric disorders in patients with ischemic heart disease: A systematic review and meta-analysis. Journal of Research in Medical Sciences. 2022;27(1):12. DOI: 10.4103/jrms.JRMS_864_20

395

Boyle SH, Samad Z, Becker RC, Williams R, Kuhn C, Ortel TL et al. Depressive Symptoms and Mental Stress–Induced Myocardial Ischemia in Patients With Coronary Heart Disease. Psychosomatic Medicine. 2013;75(9):822–31. DOI: 10.1097/PSY.0b013e3182a893ae

396

Geovanini GR, Gowdak LHW, Pereira AC, Danzi-Soares NDJ, Dourado LOC, Poppi NT et al. OSA and Depression Are Common and Independently Associated With Refractory Angina in Patients With Coronary Artery Disease. Chest. 2014;146(1):73–80. DOI: 10.1378/chest.13-2885

397

Schopfer DW, Regan M, Heidenreich PA, Whooley MA. Depressive Symptoms, Cardiac Disease Severity, and Functional Status in Patients With Coronary Artery Disease (from the Heart and Soul Study). The American Journal of Cardiology. 2016;118(9):1287–92. DOI: 10.1016/j.amjcard.2016.07.062

398

Papasavvas T, Alhashemi M, Micklewright D. Association Between Depressive Symptoms and Exercise Capacity in Patients With Heart Disease: A Meta-analysis. Journal of Cardiopulmonary Rehabilitation and Prevention. 2017;37(4):239–49. DOI: 10.1097/HCR.0000000000000193

399

Lin S, Zhang H, Ma A. The association between depression and coronary artery calcification: A meta-analysis of observational studies. Journal of Affective Disorders. 2018;232:276–82. DOI: 10.1016/j.jad.2018.02.027

400

Tusa N, Kautiainen H, Elfving P, Sinikallio S, Mäntyselkä P. Depressive symptoms decrease health-related quality of life of patients with coronary artery disease and diabetes: a 12-month follow up study in primary care. Scandinavian Journal of Primary Health Care. 2023;41(3):276–86. DOI: 10.1080/02813432.2023.2233995

401

Нонка Т.Г., Лебедева Е.В., Репин А.Н. Клинические особенности ишемической болезни сердца и 5-летняя выживаемость больных после перенесенного инфаркта миокарда на фоне депрессивных расстройств. Терапевтический архив. 2024;96(1):17–21. DOI: 10.26442/00403660.2024.01.202560

Nonka T.G., Lebedeva E.V., Repin A.N. Clinical features of coronary artery disease and 5-year survival of patients after myocardial infarction against the background of depressive disorders. Therapeutic Archive. 2024;96(1):17–21. DOI: 10.26442/00403660.2024.01.202560

402

Martens EJ, De Jonge P, Na B, Cohen BE, Lett H, Whooley MA. Scared to Death? Generalized Anxiety Disorder and Cardiovascular Events in Patients With Stable Coronary Heart Disease: The Heart and Soul Study. Archives of General Psychiatry. 2010;67(7):750–8. DOI: 10.1001/archgenpsychiatry.2010.74

403

Celano CM, Millstein RA, Bedoya CA, Healy BC, Roest AM, Huffman JC. Association between anxiety and mortality in patients with coronary artery disease: A meta-analysis. American Heart Journal. 2015;170(6):1105–15. DOI: 10.1016/j.ahj.2015.09.013

404

Tully PJ, Cosh SM, Baumeister H. The anxious heart in whose mind? A systematic review and meta-regression of factors associated with anxiety disorder diagnosis, treatment and morbidity risk in coronary heart disease. Journal of Psychosomatic Research. 2014;77(6):439–48. DOI: 10.1016/j.jpsychores.2014.10.001

405

Vaccarino V, Sullivan S, Hammadah M, Wilmot K, Al Mheid I, Ramadan R et al. Mental Stress–Induced-Myocardial Ischemia in Young Patients With Recent Myocardial Infarction: Sex Differences and Mechanisms. Circulation. 2018;137(8):794–805. DOI: 10.1161/CIRCULATIONAHA.117.030849

406

Wei J, Rooks C, Ramadan R, Shah AJ, Bremner JD, Quyyumi AA et al. Meta-Analysis of Mental Stress–Induced Myocardial Ischemia and Subsequent Cardiac Events in Patients With Coronary Artery Disease. The American Journal of Cardiology. 2014;114(2):187–92. DOI: 10.1016/j.amjcard.2014.04.022

407

Magán I, Jurado-Barba R, Casado L, Barnum H, Jeon A, Hernandez AV et al. Efficacy of psychological interventions on clinical outcomes of coronary artery disease: Systematic review and meta-analysis. Journal of Psychosomatic Research. 2022;153:110710. DOI: 10.1016/j.jpsychores.2021.110710

408

Doyle F, Freedland KE, Carney RM, De Jonge P, Dickens C, Pedersen SS et al. Hybrid Systematic Review and Network Meta-Analysis of Randomized Controlled Trials of Interventions for Depressive Symptoms in Patients With Coronary Artery Disease. Psychosomatic Medicine. 2021;83(5):423–31. DOI: 10.1097/PSY.0000000000000944

409

Dibben GO, Faulkner J, Oldridge N, Rees K, Thompson DR, Zwisler A-D et al. Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis. European Heart Journal. 2023;44(6):452–69. DOI: 10.1093/eurheartj/ehac747

410

Blumenthal JA, Sherwood A, Babyak MA, Watkins LL, Smith PJ, Hoffman BM et al. Exercise and Pharmacological Treatment of Depressive Symptoms in Patients With Coronary Heart Disease. Journal of the American College of Cardiology. 2012;60(12):1053–63. DOI: 10.1016/j.jacc.2012.04.040

411

Wang L, Sun Y, Zhan J, Wu Z, Zhang P, Wen X et al. Effects of Exercise Therapy on Anxiety and Depression in Patients With Coronary Heart Disease: A Meta-Analysis of a Randomized Controlled Study. Frontiers in Cardiovascular Medicine. 2021;8:730155. DOI: 10.3389/fcvm.2021.730155

412

Greaves D, Psaltis PJ, Ross TJ, Davis D, Smith AE, Boord MS et al. Cognitive outcomes following coronary artery bypass grafting: A systematic review and meta-analysis of 91,829 patients. International Journal of Cardiology. 2019;289:43–9. DOI: 10.1016/j.ijcard.2019.04.065

413

Evered LA, Silbert BS, Scott DA, Maruff P, Ames D. Prevalence of Dementia 7.5 Years after Coronary Artery Bypass Graft Surgery. Anesthesiology. 2016;125(1):62–71. DOI: 10.1097/ALN.0000000000001143

414

Van Dijk MR, Utens EM, Dulfer K, Al-Qezweny MN, Van Geuns R-J, Daemen J et al. Depression and anxiety symptoms as predictors of mortality in PCI patients at 10 years of follow-up. European Journal of Preventive Cardiology. 2016;23(5):552–8. DOI: 10.1177/2047487315571889

415

Zhang WY, Nan N, Song XT, Tian JF, Yang XY. Impact of depression on clinical outcomes following percutaneous coronary intervention: a systematic review and meta-analysis. BMJ Open. 2019;9(8):e026445. DOI: 10.1136/bmjopen-2018-026445

416

Song X, Song J, Shao M, Gao X, Ji F, Tian H et al. Depression predicts the risk of adverse events after percutaneous coronary intervention: A meta-analysis. Journal of Affective Disorders. 2020;266:158–64. DOI: 10.1016/j.jad.2020.01.136

417

Geulayov G, Novikov I, Dankner D, Dankner R. Symptoms of depression and anxiety and 11-year all-cause mortality in men and women undergoing coronary artery bypass graft (CABG) surgery. Journal of Psychosomatic Research. 2018;105:106–14. DOI: 10.1016/j.jpsychores.2017.11.017

418

Stenman M, Holzmann MJ, Sartipy U. Association between preoperative depression and long-term survival following coronary artery bypass surgery – A systematic review and meta-analysis. International Journal of Cardiology. 2016;222:462–6. DOI: 10.1016/j.ijcard.2016.07.216

419

Stenman M, Holzmann MJ, Sartipy U. Relation of Major Depression to Survival After Coronary Artery Bypass Grafting. The American Journal of Cardiology. 2014;114(5):698–703. DOI: 10.1016/j.amjcard.2014.05.058

420

Akosile W, Colquhoun D, Young R, Lawford B, Voisey J. The association between posttraumatic stress disorder and coronary artery disease: a meta-analysis. Australasian Psychiatry. 2018;26(5):524–30. DOI: 10.1177/1039856218789779

421

Bouchard V, Robitaille A, Perreault S, Cyr M-C, Tardif J-C, Busseuil D et al. Psychological distress, social support, and use of outpatient care among adult men and women with coronary artery disease or other non-cardiovascular chronic disease. Journal of Psychosomatic Research. 2023;165:111131. DOI: 10.1016/j.jpsychores.2022.111131

422

Pedersen SS, Smith ORF, Vries JD, Appels A, Denollet J. Course of Anxiety Symptoms Over an 18-Month Period in Exhausted Patients Post Percutaneous Coronary Intervention. Psychosomatic Medicine. 2008;70(3):349–55. DOI: 10.1097/PSY.0b013e3181656540

423

Rawashdeh SI, Ibdah R, Kheirallah KA, Al-kasasbeh A, Raffee LA, Alrabadi N et al. Prevalence Estimates, Severity, and Risk Factors of Depressive Symptoms among Coronary Artery Disease Patients after Ten Days of Percutaneous Coronary Intervention. Clinical Practice & Epidemiology in Mental Health. 2021;17(1):103–13. DOI: 10.2174/1745017902117010103

424

Williams BA, Riangwiwat T, Voyce S, Blankenship JC. Burden and Predictors of Chest Pain-Related Health-Care Utilization Following Percutaneous Coronary Intervention. The American Journal of Cardiology. 2021;160:31–9. DOI: 10.1016/j.amjcard.2021.07.051

425

De Jager TAJ, Dulfer K, Radhoe S, Bergmann MJ, Daemen J, Van Domburg RT et al. Predictive value of depression and anxiety for long-term mortality: differences in outcome between acute coronary syndrome and stable angina pectoris. International Journal of Cardiology. 2018;250:43–8. DOI: 10.1016/j.ijcard.2017.10.005

426

Zhang H-Z, Shao B, Wang Q-Y, Wang Y-H, Cao Z-Z, Chen L-L et al. Alcohol Consumption and Risk of Atrial Fibrillation: A Dose-Response Meta-Analysis of Prospective Studies. Frontiers in Cardiovascular Medicine. 2022;9:802163. DOI: 10.3389/fcvm.2022.802163

427

Yang L, Chen H, Shu T, Pan M, Huang W. Risk of incident atrial fibrillation with low-to-moderate alcohol consumption is associated with gender, region, alcohol category: a systematic review and meta-analysis. EP Europace. 2022;24(5):729–46. DOI: 10.1093/europace/euab266

428

Larsson SC, Drca N, Wolk A. Alcohol Consumption and Risk of Atrial Fibrillation. Journal of the American College of Cardiology. 2014;64(3):281–9. DOI: 10.1016/j.jacc.2014.03.048

429

Garg PK, O’Neal WT, Diez‐Roux AV, Alonso A, Soliman EZ, Heckbert S. Negative Affect and Risk of Atrial Fibrillation: MESA. Journal of the American Heart Association. 2019;8(1):e010603. DOI: 10.1161/JAHA.118.010603

430

Wang L, Ding C. Major depression disorder may causally associate with the increased atrial fibrillation risk: evidence from two-sample mendelian randomization analyses. BMC Medical Genomics. 2023;16(1):144. DOI: 10.1186/s12920-023-01565-0

431

Wu H, Li C, Li B, Zheng T, Feng K, Wu Y. Psychological factors and risk of atrial fibrillation: A meta-analysis and systematic review. International Journal of Cardiology. 2022;362:85–92. DOI: 10.1016/j.ijcard.2022.05.048

432

Zhuo C, Ji F, Lin X, Jiang D, Wang L, Tian H et al. Depression and recurrence of atrial fibrillation after catheter ablation: a meta-analysis of cohort studies. Journal of Affective Disorders. 2020;271:27–32. DOI: 10.1016/j.jad.2020.03.118

433

Shi S, Liu T, Liang J, Hu D, Yang B. Depression and Risk of Sudden Cardiac Death and Arrhythmias: A Meta-Analysis. Psychosomatic Medicine. 2017;79(2):153–61. DOI: 10.1097/PSY.0000000000000382

434

Giannone ME, Filippini T, Whelton PK, Chiari A, Vitolo M, Boriani G et al. Atrial Fibrillation and the Risk of Early‐Onset Dementia: A Systematic Review and Meta‐Analysis. Journal of the American Heart Association. 2022;11(14):e025653. DOI: 10.1161/JA-HA.122.025653

435

Koh YH, Lew LZW, Franke KB, Elliott AD, Lau DH, Thiyagarajah A et al. Predictive role of atrial fibrillation in cognitive decline: a systematic review and meta-analysis of 2.8 million individuals. EP Europace. 2022;24(8):1229–39. DOI: 10.1093/europace/euac003

436

Akintade BF, Chapa D, Friedmann E, Thomas SA. The Influence of Depression and Anxiety Symptoms on Health-Related Quality of Life in Patients With Atrial Fibrillation and Atrial Flutter. Journal of Cardiovascular Nursing. 2015;30(1):66–73. DOI: 10.1097/JCN.0000000000000107

437

Bamgbade BA, Sanghai SR, McManus DD, Lessard D, Waring ME, Forrester S et al. Psychosocial and cognitive multimorbidity and health-related quality of life and symptom burden in older adults with atrial fibrillation: The systematic assessment of geriatric elements in atrial fibrillation (SAGE-AF) cohort study. Archives of Gerontology and Geriatrics. 2020;90:104117. DOI: 10.1016/j.archger.2020.104117

438

Taylor EC, O’Neill M, Hughes LD, Moss-Morris R. Atrial fibrillation, quality of life and distress: a cluster analysis of cognitive and behavioural responses. Quality of Life Research. 2022;31(5):1415–25. DOI: 10.1007/s11136-021-03006-w

439

Sadlonova M, Salzmann S, Senges J, Celano CM, Huffman JC, Borggrefe M et al. Generalized anxiety is a predictor of impaired quality of life in patients with atrial fibrillation: Findings from the prospective observational ARENA study. Journal of Psychosomatic Research. 2024;176:111542. DOI: 10.1016/j.jpsychores.2023.111542

440

Gehi AK, Sears S, Goli N, Walker TJ, Chung E, Schwartz J et al. Psychopathology and Symptoms of Atrial Fibrillation: Implications for Therapy. Journal of Cardiovascular Electrophysiology. 2012;23(5):473–8. DOI: 10.1111/j.1540-8167.2011.02264.x

441

Thompson TS, Barksdale DJ, Sears SF, Mounsey JP, Pursell I, Gehi AK. The Effect of Anxiety and Depression on Symptoms Attributed to Atrial Fibrillation. Pacing and Clinical Electrophysiology. 2014;37(4):439–46. DOI: 10.1111/pace.12292

442

Von Eisenhart Rothe A, Hutt F, Baumert J, Breithardt G, Goette A, Kirchhof P et al. Depressed mood amplifies heart-related symptoms in persistent and paroxysmal atrial fibrillation patients: a longitudinal analysis – data from the German Competence Network on Atrial Fibrillation. Europace. 2015;17(9):1354–62. DOI: 10.1093/europace/euv018

443

Kupper N, Van Den Broek KC, Widdershoven J, Denollet J. Subjectively Reported Symptoms in Patients with Persistent Atrial Fibrillation and Emotional Distress. Frontiers in Psychology. 2013;4:192. DOI: 10.3389/fpsyg.2013.00192

444

Rosman L, Lampert R, Ramsey CM, Dziura J, Chui PW, Brandt C et al. Posttraumatic Stress Disorder and Risk for Early Incident Atrial Fibrillation: A Prospective Cohort Study of 1.1 Million Young Adults. Journal of the American Heart Association. 2019;8(19):e013741. DOI: 10.1161/JAHA.119.013741

445

Graff S, Fenger-Grøn M, Christensen B, Pedersen HS, Christensen J, Li J et al. Long-term risk of atrial fibrillation after the death of a partner. Open Heart. 2016;3(1):e000367. DOI: 10.1136/openhrt-2015-000367

446

Suzuki H, Ohira T, Takeishi Y, Hosoya M, Yasumura S, Satoh H et al. Increased prevalence of atrial fibrillation after the Great East Japan Earthquake: Results from the Fukushima Health Management Survey. International Journal of Cardiology. 2015;198:102–5. DOI: 10.1016/j.ijcard.2015.06.151

447

Wei D, Olofsson T, Chen H, Janszky I, Fang F, Ljung R et al. Death of a child and the risk of atrial fibrillation: a nationwide cohort study in Sweden. European Heart Journal. 2021;42(15):1489–95. DOI: 10.1093/eurheartj/ehaa1084

448

Voskoboinik A, Kalman JM, De Silva A, Nicholls T, Costello B, Nanayakkara S et al. Alcohol Abstinence in Drinkers with Atrial Fibrillation. New England Journal of Medicine. 2020;382(1):20–8. DOI: 10.1056/NEJMoa1817591

449

Lee S-R, Choi E-K, Jung J-H, Han K-D, Oh S, Lip GYH. Lower risk of stroke after alcohol abstinence in patients with incident atrial fibrillation: a nationwide population-based cohort study. European Heart Journal. 2021;42(46):4759–68. DOI: 10.1093/eurheartj/ehab315

450

Lee J, Roh S-Y, Yoon W-S, Kim J, Jo E, Bae D-H et al. Changes in alcohol consumption habits and risk of atrial fibrillation: a nationwide population-based study. European Journal of Preventive Cardiology. 2024;31(1):49–58. DOI: 10.1093/eurjpc/zwad270

451

Damanti S, Pasina L, Cortesi L, Rossi PD, Cesari M. Atrial Fibrillation: Possible Influences of Rate and Rhythm Control Strategy on Cognitive Performance. Journal of the American Geriatrics Society. 2018;66(11):2178–82. DOI: 10.1111/jgs.15568

452

Lee S-R, Choi E-K, Lee S-W, Han K-D, Oh S, Lip GYH. Early Rhythm Control and Incident Dementia in Patients With Atrial Fibrillation and Prior Stroke. JACC: Clinical Electrophysiology. 2024;10(7 Pt 1):1409–20. DOI: 10.1016/j.jacep.2024.03.007

453

Lampert R, Burg MM, Jamner LD, Dziura J, Brandt C, Li F et al. Effect of β-blockers on triggering of symptomatic atrial fibrillation by anger or stress. Heart Rhythm. 2019;16(8):1167–73. DOI: 10.1016/j.hrthm.2019.03.004

454

Kim D, Yang P-S, Sung J-H, Jang E, Yu HT, Kim T-H et al. Less dementia after catheter ablation for atrial fibrillation: a nationwide cohort study. European Heart Journal. 2020;41(47):4483–93. DOI: 10.1093/eurheartj/ehaa726

455

Mark DB, Anstrom KJ, Sheng S, Piccini JP, Baloch KN, Monahan KH et al. Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA. 2019;321(13):1275–85. DOI: 10.1001/jama.2019.0692

456

Al-Kaisey AM, Parameswaran R, Bryant C, Anderson RD, Hawson J, Chieng D et al. Impact of Catheter Ablation on Cognitive Function in Atrial Fibrillation. JACC: Clinical Electrophysiology. 2023;9(7 Pt 2):1024–34. DOI: 10.1016/j.jacep.2023.02.020

457

Harrison SL, Buckley BJR, Austin P, Lane DA, Lip GYH. Catheter ablation and lower risk of incident dementia and mortality in older adults with atrial fibrillation. Journal of the American Geriatrics Society. 2023;71(11):3357–66. DOI: 10.1111/jgs.18538

458

Zhang S, Zhang N, Liu L, Zheng W, Ma Z-L, Qiao S-Y et al. Global epidemiology of mental disorder in atrial fibrillation between 19982021: A systematic review and meta-analysis. World Journal of Psychiatry. 2024;14(1):179–93. DOI: 10.5498/wjp.v14.i1.179

459

Von Eisenhart Rothe AF, Goette A, Kirchhof P, Breithardt G, Limbourg T, Calvert M et al. Depression in paroxysmal and persistent atrial fibrillation patients: a cross-sectional comparison of patients enroled in two large clinical trials. EP Europace. 2014;16(6):812–9. DOI: 10.1093/europace/eut361

460

Gardarsdottir M, Sigurdsson S, Aspelund T, Rokita H, Launer LJ, Gudnason V et al. Atrial fibrillation is associated with decreased total cerebral blood flow and brain perfusion. EP Europace. 2018;20(8):1252–8. DOI: 10.1093/europace/eux220

461

Singh-Manoux A, Fayosse A, Sabia S, Canonico M, Bobak M, Elbaz A et al. Atrial fibrillation as a risk factor for cognitive decline and dementia. European Heart Journal. 2017;38(34):2612–8. DOI: 10.1093/eurheartj/ehx208

462

Marcus GM, Vittinghoff E, Whitman IR, Joyce S, Yang V, Nah G et al. Acute Consumption of Alcohol and Discrete Atrial Fibrillation Events. Annals of Internal Medicine. 2021;174(11):1503–9. DOI: 10.7326/ M21-0228

463

Gallagher C, Hendriks JML, Elliott AD, Wong CX, Rangnekar G, Middeldorp ME et al. Alcohol and incident atrial fibrillation – A systematic review and meta-analysis. International Journal of Cardiology. 2017;246:46–52. DOI: 10.1016/j.ijcard.2017.05.133

464

Stecker EC, Reinier K, Marijon E, Narayanan K, Teodorescu C, UyEvanado A et al. Public Health Burden of Sudden Cardiac Death in the United States. Circulation: Arrhythmia and Electrophysiology. 2014;7(2):212–7. DOI: 10.1161/CIRCEP.113.001034

465

Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death. New England Journal of Medicine. 2009;360(3):225–35. DOI: 10.1056/NEJ-Moa0806994

466

Murray-Thomas T, Jones ME, Patel D, Brunner E, Shatapathy CC, Motsko S et al. Risk of Mortality (Including Sudden Cardiac Death) and Major Cardiovascular Events in Atypical and Typical Antipsychotic Users: A Study with the General Practice Research Database. Cardiovascular Psychiatry and Neurology. 2013;2013:247486. DOI: 10.1155/2013/247486

467

Amaro-Hosey K, Castells X, Blanco-Silvente L, Loma-Osorio P, Capellà D. Drug-induced Sudden Death: A Scoping Review. Current Drug Safety. 2023;18(3):307–17. DOI: 10.2174/157488631766622 0525115232

468

Wang M, Szepietowska B, Polonsky B, McNitt S, Moss AJ, Zareba W et al. Risk of Cardiac Events Associated With Antidepressant Therapy in Patients With Long QT Syndrome. The American Journal of Cardiology. 2018;121(2):182–7. DOI: 10.1016/j.amjcard.2017.10.010

469

Yokohara S, Hashiguchi M, Shiga T. Psychotherapeutic drug‐induced life‐threatening arrhythmias: A retrospective analysis using the Japanese adverse drug event report database. Journal of Arrhythmia. 2023;39(6):928–36. DOI: 10.1002/joa3.12936

470

Barbui C, Bighelli I, Carrà G, Castellazzi M, Lucii C, Martinotti G et al. Antipsychotic Dose Mediates the Association between Polypharmacy and Corrected QT Interval. PLOS ONE. 2016;11(2):e0148212. DOI: 10.1371/journal.pone.0148212

471

Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C et al. Genotype-Phenotype Correlation in the Long-QT Syndrome: Gene-Specific Triggers for Life-Threatening Arrhythmias. Circulation. 2001;103(1):89–95. DOI: 10.1161/01.CIR.103.1.89

472

Hintsa T, Määttänen I, Hintsanen M, Swan H, Toivonen L, Kontula K et al. Work Stress and the Long QT Syndrome: High Job Strain and Effort–Reward Imbalance at Work Associated With Arrhythmic Risk in the Long QT Syndrome. Journal of Occupational & Environmental Medicine. 2013;55(12):1387–93. DOI: 10.1097/JOM.0000000000000026

473

Shimizu W, Noda T, Takaki H, Nagaya N, Satomi K, Kurita T et al. Diagnostic value of epinephrine test for genotyping LQT1, LQT2, and LQT3 forms of congenital long QT syndrome. Heart Rhythm. 2004;1(3):276–83. DOI: 10.1016/j.hrthm.2004.04.021

474

Dunbar SB, Dougherty CM, Sears SF, Carroll DL, Goldstein NE, Mark DB et al. Educational and Psychological Interventions to Improve Outcomes for Recipients of Implantable Cardioverter Defibrillators and Their Families: A Scientific Statement From the American Heart Association. Circulation. 2012;126(17):2146–72. DOI: 10.1161/CIR.0b013e31825d59fd

475

Ghezzi ES, Sharman RLS, Selvanayagam JB, Psaltis PJ, Sanders P, Astley JM et al. Burden of mood symptoms and disorders in implantable cardioverter defibrillator patients: a systematic review and meta-analysis of 39 954 patients. Europace. 2023;25(6):euad130. DOI: 10.1093/europace/euad130

476

Miller JL, Thylén I, Elayi SC, Etaee F, Fleming S, Czarapata MM et al. Multi-morbidity burden, psychological distress, and quality of life in implantable cardioverter defibrillator recipients: Results from a nationwide study. Journal of Psychosomatic Research. 2019;120:39–45. DOI: 10.1016/j.jpsychores.2019.03.006

477

Januszkiewicz Ł, Barra S, Providencia R, Conte G, De Asmundis C, Chun JKR et al. Long-term quality of life and acceptance of implantable cardioverter-defibrillator therapy: results of the European Heart Rhythm Association survey. EP Europace. 2022;24(5):860–7. DOI: 10.1093/europace/euac011

478

Ryan K, Benz P, Zosel A, Farkas A, Theobald J. QTc Prolongation in Poison Center Exposures to CredibleMeds List of Substances with “Known Risk of Torsades de Pointes”. Cardiovascular Toxicology. 2022;22(9):866–77. DOI: 10.1007/s12012-022-09764-4

479

Riad FS, Davis AM, Moranville MP, Beshai JF. Drug-Induced QTc Prolongation. The American Journal of Cardiology. 2017;119(2):280–3. DOI: 10.1016/j.amjcard.2016.09.041

480

Niemeijer MN, Van Den Berg ME, Franco OH, Hofman A, Kors JA, Stricker BH et al. Drugs and ventricular repolarization in a general population: the Rotterdam Study. Pharmacoepidemiology and Drug Safety. 2015;24(10):1036–41. DOI: 10.1002/pds.3853

481

Das B, Rawat VS, Ramasubbu SK, Kumar B. Frequency, characteristics and nature of risk factors associated with use of QT interval prolonging medications and related drug-drug interactions in a cohort of psychiatry patients. Therapies. 2019;74(6):599–609. DOI: 10.1016/j. therap.2019.03.008

482

Fayssoil A, Issi J, Guerbaa M, Raynaud J-C, Heroguelle V. Torsade de pointes induced by citalopram and amiodarone. Annales de Cardiologie et d’Angéiologie. 2011;60(3):165–8. DOI: 10.1016/j.ancard.2010.12.002

483

Simpson TF, Salazar JW, Vittinghoff E, Probert J, Iwahashi A, Olgin JE et al. Association of QT-Prolonging Medications With Risk of Autopsy-Defined Causes of Sudden Death. JAMA Internal Medicine. 2020;180(5):698–706. DOI: 10.1001/jamainternmed.2020.0148

484

Polcwiartek C, Kragholm K, Schjerning O, Graff C, Nielsen J. Cardiovascular safety of antipsychotics: a clinical overview. Expert Opinion on Drug Safety. 2016;15(5):679–88. DOI: 10.1517/14740338.2016.1161021

485

NHS Foundation. Guidance on the Use of Antipsychotics. 2022. [Internet] Available at: https://pdf4pro.com/view/guidance-on-the-useof-antipsychotics-77486b.html

486

American Psychiatric Association. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. - Washington, DC: American Psychiatric Association; 2020. - 312p. ISBN 978-0-89042-469-8. Available at: https://psychiatryonline.org/doi/epdf/10.1176/appi.books.9780890424841

487

Bundgaard JS, Thune JJ, Nielsen JC, Videbæk R, Haarbo J, Bruun NE et al. The impact of implantable cardioverter-defibrillator implantation on health-related quality of life in the DANISH trial. EP Europace. 2019;21(6):900–8. DOI: 10.1093/europace/euz018

488

Pan Y, Cai W, Cheng Q, Dong W, An T, Yan J. Association between anxiety and hypertension: a systematic review and meta-analysis of epidemiological studies. Neuropsychiatric Disease and Treatment. 2015;11:1121–30. DOI: 10.2147/NDT.S77710

489

Wu E-L, Chien I-C, Lin C-H. Increased risk of hypertension in patients with anxiety disorders: A population-based study. Journal of Psychosomatic Research. 2014;77(6):522–7. DOI: 10.1016/j.jpsychores.2014.10.006

490

Meng L, Chen D, Yang Y, Zheng Y, Hui R. Depression increases the risk of hypertension incidence: a meta-analysis of prospective cohort studies. Journal of Hypertension. 2012;30(5):842–51. DOI: 10.1097/HJH.0b013e32835080b7

491

Wu E-L, Chien I-C, Lin C-H, Chou Y-J, Chou P. Increased risk of hypertension in patients with major depressive disorder: A population-based study. Journal of Psychosomatic Research. 2012;73(3):169–74. DOI: 10.1016/j.jpsychores.2012.07.002

492

Lim L-F, Solmi M, Cortese S. Association between anxiety and hypertension in adults: A systematic review and meta-analysis. Neuroscience & Biobehavioral Reviews. 2021;131:96–119. DOI: 10.1016/j.neubiorev.2021.08.031

493

Abouzeid M, Kelsall HL, Forbes AB, Sim MR, Creamer MC. Posttraumatic stress disorder and hypertension in Australian veterans of the 1991 Gulf War. Journal of Psychosomatic Research. 2012;72(1):33–8. DOI: 10.1016/j.jpsychores.2011.08.002

494

Sumner JA, Kubzansky LD, Roberts AL, Gilsanz P, Chen Q, Winning A et al. Post-traumatic stress disorder symptoms and risk of hypertension over 22 years in a large cohort of younger and middleaged women. Psychological Medicine. 2016;46(15):3105–16. DOI: 10.1017/S0033291716001914

495

Abell JG, Kivimäki M, Dugravot A, Tabak AG, Fayosse A, Shipley M et al. Association between systolic blood pressure and dementia in the Whitehall II cohort study: role of age, duration, and threshold used to define hypertension. European Heart Journal. 2018;39(33):3119–25. DOI: 10.1093/eurheartj/ehy288

496

Emdin CA, Rothwell PM, Salimi-Khorshidi G, Kiran A, Conrad N, Callender T et al. Blood Pressure and Risk of Vascular Dementia: Evidence From a Primary Care Registry and a Cohort Study of Transient Ischemic Attack and Stroke. Stroke. 2016;47(6):1429–35. DOI: 10.1161/STROKEAHA.116.012658

497

Li C, Zhu Y, Ma Y, Hua R, Zhong B, Xie W. Association of Cumulative Blood Pressure With Cognitive Decline, Dementia, and Mortality. Journal of the American College of Cardiology. 2022;79(14):1321–35. DOI: 10.1016/j.jacc.2022.01.045

498

Cunningham EL, Todd SA, Passmore P, Bullock R, McGuinness B. Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of cognitive impairment and dementia. Cochrane Database of Systematic Reviews. 2021;5:CD004034. DOI: 10.1002/14651858.CD004034.pub4

499

Hughes D, Judge C, Murphy R, Loughlin E, Costello M, Whiteley W et al. Association of Blood Pressure Lowering With Incident Dementia or Cognitive Impairment: A Systematic Review and Meta-analysis. JAMA. 2020;323(19):1934–44. DOI: 10.1001/jama.2020.4249

500

Peters R, Xu Y, Fitzgerald O, Aung HL, Beckett N, Bulpitt C et al. Blood pressure lowering and prevention of dementia: an individual patient data meta-analysis. European Heart Journal. 2022;43(48):4980–90. DOI: 10.1093/eurheartj/ehac584

501

Forette F. The Prevention of Dementia With Antihypertensive Treatment: New Evidence From the Systolic Hypertension in Europe (SystEur) Study. Archives of Internal Medicine. 2002;162(18):2046–52. DOI: 10.1001/archinte.162.18.2046

502

Wang L, Liu Q, Sun D, Xie J, Lao D, Zhang L. Effects of Combination Treatment in Hypertensive Patients with Depression: A Systematic Review and Meta-Analysis of 27 Randomized Controlled Trials. Therapeutics and Clinical Risk Management. 2022;18:197–211. DOI: 10.2147/TCRM.S347622

503

Graham N, Ward J, Mackay D, Pell JP, Cavanagh J, Padmanabhan S et al. Impact of major depression on cardiovascular outcomes for individuals with hypertension: prospective survival analysis in UK Biobank. BMJ Open. 2019;9(9):e024433. DOI: 10.1136/bmjopen-2018-024433

504

Ogedegbe G, Pickering TG, Clemow L, Chaplin W, Spruill TM, Albanese GM et al. The Misdiagnosis of Hypertension: The Role of Patient Anxiety. Archives of Internal Medicine. 2008;168(22):2459–65. DOI: 10.1001/archinte.168.22.2459

505

Spruill TM, Pickering TG, Schwartz JE, Mostofsky E, Ogedegbe G, Clemow L et al. The impact of perceived hypertension status on anxiety and the white coat effect. Annals of Behavioral Medicine. 2007;34(1):1–9. DOI: 10.1007/BF02879915

506

Jhalani J, Goyal T, Clemow L, Schwartz JE, Pickering TG, Gerin W. Anxiety and outcome expectations predict the white-coat effect: Blood Pressure Monitoring. 2005;10(6):317–9. DOI: 10.1097/00126097-200512000-00006

507

Bhanu C, Nimmons D, Petersen I, Orlu M, Davis D, Hussain H et al. Drug-induced orthostatic hypotension: A systematic review and meta-analysis of randomised controlled trials. PLOS Medicine. 2021;18(11):e1003821. DOI: 10.1371/journal.pmed.1003821

508

Licht CMM, De Geus EJC, Seldenrijk A, Van Hout HPJ, Zitman FG, Van Dyck R et al. Depression Is Associated With Decreased Blood Pressure, but Antidepressant Use Increases the Risk for Hypertension. Hypertension. 2009;53(4):631–8. DOI: 10.1161/HYPERTENSIONAHA.108.126698

509

Breeden M, Brieler J, Salas J, Scherrer JF. Antidepressants and Incident Hypertension in Primary Care Patients. The Journal of the Ameri can Board of Family Medicine. 2018;31(1):22–8. DOI: 10.3122/jabfm.2018.01.170234

510

Wathra R, Mulsant BH, Thomson L, Goldberger KW, Lenze EJ, Karp JF et al. Hypertension and orthostatic hypotension with venlafaxine treatment in depressed older adults. Journal of Psychopharmacology. 2020;34(10):1112–8. DOI: 10.1177/0269881120944154

511

Thase ME. Effects of Venlafaxine on Blood Pressure: A Meta-Analysis of Original Data From 3744 Depressed Patients. The Journal of Clinical Psychiatry. 1998;59(10):502–8. DOI: 10.4088/JCP.v59n1002

512

Johnson EM, Whyte E, Mulsant BH, Pollock BG, Weber E, Begley AE et al. Cardiovascular Changes Associated With Venlafaxine in the Treatment of Late-Life Depression. The American Journal of Geriatric Psychiatry. 2006;14(9):796–802. DOI: 10.1097/01.JGP.0000204328.50105.b3

513

Li Z, Li Y, Chen L, Chen P, Hu Y. Prevalence of Depression in Patients With Hypertension: A Systematic Review and Meta-Analysis. Medicine. 2015;94(31):e1317. DOI: 10.1097/MD.0000000000001317

514

Williamson JD, Pajewski NM, Auchus AP, Bryan RN, Chelune G, Cheung AK et al. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA. 2019;321(6):553–61. DOI: 10.1001/jama.2018.21442

515

Stuhec M, Keuschler J, Serra-Mestres J, Isetta M. Effects of different antihypertensive medication groups on cognitive function in older patients: A systematic review. European Psychiatry. 2017;46:1–15. DOI: 10.1016/j.eurpsy.2017.07.015

516

Den Brok MGHE, Van Dalen JW, Abdulrahman H, Larson EB, Van Middelaar T, Van Gool WA et al. Antihypertensive Medication Classes and the Risk of Dementia: A Systematic Review and Network Meta-Analysis. Journal of the American Medical Directors Association. 2021;22(7):1386-1395.e15. DOI: 10.1016/j.jamda.2020.12.019

517

Chen YJ, Li LJ, Tang WL, Song JY, Qiu R, Li Q et al. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database of Systematic Reviews. 2018;11:CD008170. DOI: 10.1002/14651858.CD008170.pub3

518

Breeden M, Gillis A, Salas J, Scherrer JF. Antidepressant treatment and blood pressure control in patients with comorbid depression and treatment resistant hypertension. Journal of Psychosomatic Research. 2022;153:110692. DOI: 10.1016/j.jpsychores.2021.110692

519

Turvey CL, Schultz K, Arndt S, Wallace RB, Herzog R. Prevalence and Correlates of Depressive Symptoms in a Community Sample of People Suffering from Heart Failure. Journal of the American Geriatrics Society. 2002;50(12):2003–8. DOI: 10.1046/j.1532-5415.2002.50612.x

520

Chobufo MD, Khan S, Agbor VN, Rahman E, Foryoung JB, Jolayemi A et al. 10-Year trend in the prevalence and predictors of depression among patients with heart failure in the USA from 2007–2016. International Journal of Cardiology. 2020;301:123–6. DOI: 10.1016/j.ijcard.2019.09.028

521

Angermann CE, Gelbrich G, Störk S, Schowalter M, Deckert J, Ertl G et al. Somatic correlates of comorbid major depression in patients with systolic heart failure. International Journal of Cardiology. 2011;147(1):66–73. DOI: 10.1016/j.ijcard.2009.07.044

522

Khodneva Y, Goyal P, Levitan EB, Jackson EA, Oparil S, Sterling MR et al. Depressive Symptoms and Incident Hospitalization for Heart Failure: Findings From the REGARDS Study. Journal of the American Heart Association. 2022;11(7):e022818. DOI: 10.1161/JA-HA.121.022818

523

Gustad LT, Laugsand LE, Janszky I, Dalen H, Bjerkeset O. Symptoms of anxiety and depression and risk of heart failure: the HUNT Study. European Journal of Heart Failure. 2014;16(8):861–70. DOI: 10.1002/ejhf.133

524

Garfield LD, Scherrer JF, Hauptman PJ, Freedland KE, Chrusciel T, Balasubramanian S et al. Association of Anxiety Disorders and Depression With Incident Heart Failure. Psychosomatic Medicine. 2014;76(2):128–36. DOI: 10.1097/PSY.0000000000000027

525

Lossnitzer N, Herzog W, Störk S, Wild B, Müller-Tasch T, Lehmkuhl E et al. Incidence rates and predictors of major and minor depression in patients with heart failure. International Journal of Cardiology. 2013;167(2):502–7. DOI: 10.1016/j.ijcard.2012.01.062

526

Machado MO, Veronese N, Sanches M, Stubbs B, Koyanagi A, Thompson T et al. The association of depression and all-cause and cause-specific mortality: an umbrella review of systematic reviews and meta-analyses. BMC Medicine. 2018;16(1):112. DOI: 10.1186/ s12916-018-1101-z

527

Patel N, Chakraborty S, Bandyopadhyay D, Amgai B, Hajra A, Atti V et al. Association between depression and readmission of heart failure: A national representative database study. Progress in Cardiovascular Diseases. 2020;63(5):585–90. DOI: 10.1016/j.pcad.2020.03.014

528

Kewcharoen J, Tachorueangwiwat C, Kanitsoraphan C, Saowapa S, Nitinai N, Vutthikraivit W et al. Association between depression and increased risk of readmission in patients with heart failure: a systematic review and meta-analysis. Minerva Cardiology and Angiology. 2021;69(4):389–97. DOI: 10.23736/S2724-5683.20.05346-3

529

Gathright EC, Goldstein CM, Josephson RA, Hughes JW. Depression increases the risk of mortality in patients with heart failure: A meta-analysis. Journal of Psychosomatic Research. 2017;94:82–9. DOI: 10.1016/j.jpsychores.2017.01.010

530

IsHak WW, Hamilton MA, Korouri S, Diniz MA, Mirocha J, Hedrick R et al. Comparative Effectiveness of Psychotherapy vs Antidepressants for Depression in Heart Failure: A Randomized Clinical Trial. JAMA Network Open. 2024;7(1):e2352094. DOI: 10.1001/jamanetworkopen.2023.52094

531

Angermann CE, Gelbrich G, Störk S, Gunold H, Edelmann F, Wachter R et al. Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial. JAMA. 2016;315(24):2683–93. DOI: 10.1001/jama.2016.7635

532

O’Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD et al. Safety and Efficacy of Sertraline for Depression in Patients With Heart Failure. Journal of the American College of Cardiology. 2010;56(9):692–9. DOI: 10.1016/j.jacc.2010.03.068

533

Hedrick R, Korouri S, Tadros E, Darwish T, Cortez V, Triay D et al. The impact of antidepressants on depressive symptom severity, quality of life, morbidity, and mortality in heart failure: a systematic review. Drugs in Context. 2020;9:1–22. DOI: 10.7573/dic.2020-5-4

534

Zambrano J, Celano CM, Januzzi JL, Massey CN, Chung W, Millstein RA et al. Psychiatric and Psychological Interventions for Depression in Patients With Heart Disease: A Scoping Review. Journal of the American Heart Association. 2020;9(22):e018686. DOI: 10.1161/JAHA.120.018686

535

Jeyanantham K, Kotecha D, Thanki D, Dekker R, Lane DA. Effects of cognitive behavioural therapy for depression in heart failure patients: a systematic review and meta-analysis. Heart Failure Reviews. 2017;22(6):731–41. DOI: 10.1007/s10741-017-9640-5

536

Chernoff RA, Messineo G, Kim S, Pizano D, Korouri S, Danovitch I et al. Psychosocial Interventions for Patients With Heart Failure and Their Impact on Depression, Anxiety, Quality of Life, Morbidity, and Mortality: A Systematic Review and Meta-Analysis. Psychosomatic Medicine. 2022;84(5):560–80. DOI: 10.1097/PSY.0000000000001073

537

Tu R-H, Zeng Z-Y, Zhong G-Q, Wu W-F, Lu Y-J, Bo Z-D et al. Effects of exercise training on depression in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials: Effects of exercise training on depression in HF: a systematic review. European Journal of Heart Failure. 2014;16(7):749–57. DOI: 10.1002/ejhf.101

538

Das A, Roy B, Schwarzer G, Silverman MG, Ziegler O, Bandyopadhyay D et al. Comparison of treatment options for depression in heart failure: A network meta-analysis. Journal of Psychiatric Research. 2019;108:7–23. DOI: 10.1016/j.jpsychires.2018.10.007

539

Suzuki T, Shiga T, Kuwahara K, Kobayashi S, Suzuki S, Nishimura K et al. Impact of clustered depression and anxiety on mortality and re-hospitalization in patients with heart failure. Journal of Cardiology. 2014;64(6):456–62. DOI: 10.1016/j.jjcc.2014.02.031

540

Alhurani AS, Dekker RL, Abed MA, Khalil A, Al Zaghal MH, Lee KS et al. The Association of Comorbid Symptoms of Depression and Anxi ety With All-Cause Mortality and Cardiac Rehospitalization in Patients With Heart Failure. Psychosomatics. 2015;56(4):371–80. DOI: 10.1016/j.psym.2014.05.022

541

Zwas DR, Keren A, Amir O, Gotsman I. Treatment of Heart Failure Patients with Anxiolytics Is Associated with Adverse Outcomes, with and without Depression. Journal of Clinical Medicine. 2020;9(12):3967. DOI: 10.3390/jcm9123967

542

Sato Y, Yoshihisa A, Hotsuki Y, Watanabe K, Kimishima Y, Kiko T et al. Associations of Benzodiazepine With Adverse Prognosis in Heart Failure Patients With Insomnia. Journal of the American Heart Association. 2020;9(7):e013982. DOI: 10.1161/JAHA.119.013982

543

Chi Chuang, Fu-Chih Hsiao, Yu-Wen Cheng, Chia-Pin Lin, Ying-Chang Tung, Chia-Tung Wu et al. Benzodiazepines in Patients with Heart Failure and Reduced Ejection Fraction. Acta Cardiologica Sinica. 2022;38(5):573–83. DOI: 10.6515/ACS.202209_38(5).20220406A

544

Ribeirinho-Soares P, Madureira S, Elias C, Gouveia R, Neves A, Amorim M et al. Benzodiazepines use and mortality in chronic heart failure. Polish Archives of Internal Medicine. 2023;133:16464. DOI: 10.20452/pamw.16464

545

He W, Zhou Y, Ma J, Wei B, Fu Y. Effect of antidepressants on death in patients with heart failure: a systematic review and meta-analysis. Heart Failure Reviews. 2020;25(6):919–26. DOI: 10.1007/s10741-019-09850-w

546

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021;42(36):3599–726. DOI: 10.1093/eurheartj/ehab368

The authors declare that there are no conflicts of interest present.